Поиск патентов

Настройки

Глубина выборки

Укажите год

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Ключевые слова. Может быть несколько по одной на строку

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка

Автор

Ведите корректный номера.

Владелец

Ведите корректный номера.

Классы IPC

Ведите корректный номера.

Классы CPC

Ведите корректный номера.

Начиная с года

Укажите год

Заканчивая годом

Укажите год

Применить Всего найдено 7359. Отображено 100.

23-02-2012 дата публикации

Crystal structure of glutaminyl cyclase

Номер: US20120045815A1

Автор: Birgit Koch, Christoph Parthier, David Ruiz-Carillo, Jens-Ulrich Rahfeld, Michael Wermann, Milton T. Stubbs, Stephan Schilling

Принадлежит: PROBIODRUG AG

A novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.

Подробнее

Номер записи: 1

29-03-2012 дата публикации

Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof

Номер: US20120076806A1

Автор: Andrew R. Mendelsohn, James Larrick, Keith N. Haffer

Принадлежит: BRAASCH BIOTECH LLC

Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.

Подробнее

Номер записи: 2

19-04-2012 дата публикации

Dgat genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants

Номер: US20120096588A1

Автор: Howard Glenn Damude, Kevin G. Ripp, Kevin L. Stecca, Knut Meyer

Принадлежит: EI Du Pont de Nemours and Co

Transgenic soybean seed having increased total fatty acid content of at least 10% and altered fatty acid profiles when compared to the total fatty acid content of non-transgenic, null segregant soybean seed are described. DGAT genes from oleaginous organisms are used to achieve the increase in seed storage lipids.

Подробнее

Номер записи: 3

03-05-2012 дата публикации

Use of LCAT for Treating Anemia and Red Blood Cell Dysfunction

Номер: US20120107298A1

Автор: Brian Krause, Bruce J. Auerbach, Reynold Homan

Принадлежит: Alphacore Pharma LLC

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.

Подробнее

Номер записи: 4

26-07-2012 дата публикации

Genes for Enhanced Lipid Metabolism for Accumulation of Lipids

Номер: US20120190115A1

Автор: Bertrand Vick, Oliver Kilian

Принадлежит: Aurora Algae Inc

Provided herein are exemplary genes, constructs and methods for the formation of triacylglycerols (TAGs). The exemplary genes include a phosphatic acid phosphohydrolase (PA Hydrolase) gene, a diacylglycerol o-acyltransferase (DAGAT2A) gene, and a phospholipid:diacylglycerol acyltransferase (LROI) gene.

Подробнее

Номер записи: 5

25-10-2012 дата публикации

Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices

Номер: US20120270810A1

Автор: Guy Tomer, Orahn Preiss-Bloom

Принадлежит: Lifebond Ltd

Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.

Подробнее

Номер записи: 6

01-11-2012 дата публикации

Diacylglycerol acyltransferase genes and use thereof

Номер: US20120277451A1

Автор: Misa Ochiai

Принадлежит: Suntory Holdings Ltd

It is an object to provide a novel diacylglycerol acyltransferase. The present invention relates to a diacylglycerol acyltransferase, a polynucleotide encoding the same, and so on. The present invention provides a polynucleotide comprising the nucleotide sequence of, e.g., SEQ ID NO: 1 or 4, a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2, an expression vector and transformant comprising the polynucleotide, a method for producing a lipid or fatty acid composition using the transformant, or a food, etc. comprising the lipid or fatty acid produced by the method.

Подробнее

Номер записи: 7

06-12-2012 дата публикации

Thermophilic thermoanaerobacter italicus subsp. marato having high alcohol productivity

Номер: US20120309065A1

Автор: Marie Just Mikkelsen, Rasmus Lund ANDERSEN, Thomas Kvist

Принадлежит: BIOGASOL IPR APS

Strict anaerobic thermophilic bacterium belonging to the group of Thermoanaerobacter italicus subsp. marato subsp. nov. and mutants and derivatives thereof. The bacterium is particularly suitable for the production of fermentation products such as ethanol, lactic acid, acetic acid and hydrogen from lignocellulosic biomass.

Подробнее

Номер записи: 8

17-01-2013 дата публикации

Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene

Номер: US20130017581A1

Автор: Hiroyuki Anzai, Kentaro Yamamoto, Koichiro Murashima, Kouji Yanai, Naomi Sumida, Sato Aihara

Принадлежит: Individual

There is provided a nucleic acid construct comprising a pyripyropene biosynthetic gene cluster and a marker gene. The nucleic acid construct according to the present invention provides an inexpensive and highly productive method for producing pyripyropene.

Подробнее

Номер записи: 9

14-03-2013 дата публикации

Cell-free preparation of carbapenems

Номер: US20130065878A1

Автор: Daniel Klein-Marcuschamer, William Jeremy Blake

Принадлежит: Greenlight Biosciences Inc

Provided herein are cell-free systems for generating carbapenems, e.g., a compound of the Formula (I): or salts thereof; wherein , R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are defined herein. Also provided are pharmaceutical compositions comprising a compound generated by the inventive cell-free system, and use of these compounds and compositions for the treatment of bacterial infections.

Подробнее

Номер записи: 10

13-06-2013 дата публикации

BARD1 Isoforms in Lung and Colorectal Cancer and Use Thereof

Номер: US20130149711A1

Автор: Irmgard Irminger-Finger, yong-qiang Zhang

Принадлежит: HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVE

The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.

Подробнее

Номер записи: 11

13-06-2013 дата публикации

Marchantiales-derived unsaturated fatty acid synthetase genes and use of the same

Номер: US20130152229A1

Автор: Kanji Ohyama

Принадлежит: Suntory Holdings Ltd

A Δ5 fatty acid desaturase gene, a Δ6 fatty acid desaturase gene, and a Δ6 fatty-acid-chain elongase gene are isolated from a single species of Marchantiales. By introducing these genes into higher plants, transformed plants which can produce arachidonic acid and eicosapentaenoic acid (EPA) are obtained.

Подробнее

Номер записи: 12

18-07-2013 дата публикации

Method of meristem excision and transformation

Номер: US20130185830A1

Автор: Anatoly Rivlin, Brian J. Martinell, Erik Dersch, Richard J. Heinzen, Xudong Ye, Yuechun Wan

Принадлежит: MONSANTO TECHNOLOGY LLC

The present invention relates to excision of explant material comprising meristematic tissue from cotton seeds. Methods for tissue preparation, storage, transformation, and selection or identification of transformed plants are disclosed, as are transformable meristem tissues and plants produced by such methods, and apparati for tissue preparation.

Подробнее

Номер записи: 13

01-08-2013 дата публикации

Composition and method for reducing atherosclerotic lesions

Номер: US20130195770A1

Автор: Bent Raungaard, Charlotte Horsmans Poulsen, Jorn Borch Soe, Leif Schauser, Marta Jadwiga Bauerek

Принадлежит: DUPONT NUTRITION BIOSCIENCES APS

The present invention relates to a method for reducing cholesterol absorption and the occurrence of atherosclerotic lesions in an animal comprising administering to the animal a composition comprising an effective amount of at least one cholesterol ester.

Подробнее

Номер записи: 14

22-08-2013 дата публикации

Crystal structure of glutaminyl cyclase

Номер: US20130217090A1

Автор: Birgit Koch, Christoph Parthier, David Ruiz-Carillo, Jens-Ulrich Rahfeld, Michael Wermann, Milton T. Stubbs, Stephan Schilling

Принадлежит: PROBIODRUG AG

Novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.

Подробнее

Номер записи: 15

29-08-2013 дата публикации

Recombinant therapeutic glycine n-acyltransferase

Номер: US20130224175A1

Автор: Alberdina Aike Van Dijk, Christoffel Petrus Stephanus Badenhorst, Lodewyk Jacobus Mienie, Rencia Van Der Sluis

Принадлежит: NORTH WEST UNIVERSITY

This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 2.1.3.13)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in the expression host to form an expression piasmid; transforming the host with the expression piasmid to form an expression system; expressing the GLYAT gene in the expression system; and separating the expressed GLYAT from the expression system.

Подробнее

Номер записи: 16

29-08-2013 дата публикации

Recombinant microorganisms and uses therefor

Номер: US20130224838A1

Автор: Fungmin Liew, Michael Koepke, Sean Simpson, Wendy Chen

Принадлежит: Individual

The invention provides, inter alia, methods for the production of acetone, isopropanol and/or precursors of acetone and/or isopropanol by microbial fermentation of substrates comprising CO, genetically modified microorganisms of use in such methods, nucleic acids suitable for preparation of genetically modified microorganisms, a novel alcohol dehydrogenase and nucleic acids encoding same.

Подробнее

Номер записи: 17

24-10-2013 дата публикации

Compositions and methods for inhibiting expression of the alas1 gene

Номер: US20130281511A1

Автор: Brian Bettencourt, Kevin Fitzgerald, Makiko Yasuda, Robert J. Desnick, William Querbes

Принадлежит: Individual

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Подробнее

Номер записи: 18

19-12-2013 дата публикации

Lipid comprising polyunsaturated fatty acids

Номер: US20130338388A1

Автор: James Robertson Petrie, Robert Charles de Feyter, Surinder Pal Singh

Принадлежит: Commonwealth Scientific and Industrial Research Organization CSIRO, Grains Research and Development Corp, Nuseed Pty Ltd

The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.

Подробнее

Номер записи: 19

26-12-2013 дата публикации

Recombinant microorganisms make biodiesel

Номер: US20130344547A1

Автор: Fungmin Liew, Michael Koepke

Принадлежит: Lanzatech New Zealand Ltd

A carboxydotrophic acetogenic recombinant microorganism is modified so that it produces biodiesel and optionally one or more other products by fermentation of a substrate comprising CO. Biodiesel is produced by microbial fermentation of a substrate comprising CO. The recombinant microorganism is modified to express one or more exogenous enzymes in the biodiesel biosynthesis pathway not present in a parental microorganism from which the recombinant microorganism is derived. The one or more enzymes comprise a nonspecific acyltransferase.

Подробнее

Номер записи: 20

20-02-2014 дата публикации

Transglutaminase-2 inhibitors and uses thereof

Номер: US20140050779A1

Автор: Louis Tong, Roger W. Beuerman, VELUCHAMY Amutha Barathi

Принадлежит: SINGAPORE HEALTH SERVICES PTE LTD

The present invention refers to a method of treating a disease or disorder associated with the expression of at least one transgluaminase-2 and a method of identifying a candidate transglutaminase-2 inhibitor.

Подробнее

Номер записи: 21

20-03-2014 дата публикации

Methods and compositions for preventing norleucine misincorporation into proteins

Номер: US20140081003A1

Автор: Karthik VEERAVALLI, Michael W. Laird

Принадлежит: Genentech Inc

The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.

Подробнее

Номер записи: 22

03-01-2019 дата публикации

BIOFILMS, COMPONENTS AND METHODS OF USE TO REDUCE BIOFOULING AND CONTAMINATION

Номер: US20190000090A1

Автор: Kumar Manish, Wood Thammajun L., Wood Thomas K.

Принадлежит:

Biofilms are provided which are capable of regulating their own thickness, reducing contamination and preventing biofouling. Constructs are introduced into bacteria that comprise nucleic acid molecules encoding an autoinducer synthase polypeptide, a transcriptional regulator and a biofilm dispersal protein. Nucleic acid molecules may also be introduced which encode a nitric oxide synthase, an epoxide hydrolase, or both. Biofilms of the bacteria may be used to reduce biofouling and contamination of a surface. 1. A method of producing a living self-controlled biofilm of engineered bacteria cells on a surface , said method comprising: i. a nucleic acid molecule encoding an autoinducer synthase polypeptide;', 'ii. a nucleic acid molecule encoding a transcriptional regulator, capable of being activated by said autoinducer synthase polypeptide; and', 'iii. a nucleic acid molecule encoding a biofilm dispersal protein to produce said at least one engineered bacteria cell comprising said construct; and, 'a) producing at least one engineered bacteria cell by introducing into said at least one bacterial cell a quorum sensing nucleic acid construct, comprising,'}b) producing a self-controlled biofilm of said at least one engineered bacteria-cells, wherein said quorum sensing nucleic acid construct in response to activation of said transcriptional regulatory and production of said biofilm dispersal protein reduces the thickness of said self-controlled biofilm compared to biofilm not comprising said quorum sensing nucleic acid construct.24.-. (canceled)5. The method of claim 1 , further comprising introducing into said at least one bacterial cell a nucleic acid molecule encoding nitric oxide synthase.6. The method of claim 1 , further comprising introducing into said bacterial cell a nucleic acid molecule encoding epoxide hydrolase.78.-. (canceled)9. The method of claim 1 , wherein said thickness of said biofilm is at least six fold less than said biofilm not comprising said ...

Подробнее

Номер записи: 23

02-01-2020 дата публикации

ATTENUATION OF NEUROPATHIC PAIN AFTER SPINAL CORD INJURY

Номер: US20200000775A1

Автор: Geddes James W., Yu Chen Guang

Принадлежит:

Methods for treating neuropathic pain caused by a traumatic spinal cord injury are described. A method comprising administering an effective amount of flubendazole, an α-tubulin acetylation inhibitor, an endosomal NR1 and pERK1/2 inhibitor, a mitochondrial cyclin b1 inhibitor, a microtubule destabilizing drug, or combinations thereof to the patient suffering from the traumatic spinal cord injury. Also described is a method for preventing neuropathic pain in a patient with a spinal cord injury at risk for developing neuropathic pain comprising administering administrating an effective amount of flubendazole to a patient with the spinal cord injury at risk of developing neuropathic pain. 1. A method of treating pain in a patient having a traumatic spinal cord injury , comprising:administering an effective amount of flubendazole, an α-tubulin acetylation inhibitor, an endosomal NR1 and pERK1/2 inhibitor, a mitochondrial cyclin b1 inhibitor, a microtubule destabilizing drug, or combinations thereof to the patient.2. The method of claim 1 , wherein the pain is neuropathic pain.3. The method of claim 1 , wherein the pain is caused by excitotoxic neural injury.4. The method of claim 1 , wherein the patient is at risk for developing neuropathic pain.5. The method of claim 4 , comprising administering an effective amount of flubendazole to the patient.6. The method of claim 5 , wherein the treatment comprises substantially preventing neuropathic pain in the patient. This application is related to U.S. Provisional Application Ser. No. 62/691,969 filed Jun. 29, 2018, the entire disclosure of which is incorporated herein by this reference.This invention was made with government support under grant number UL1TR000117 awarded by the National Institutes of Health. The government has certain rights in the invention.The present invention relates to a method of using flubendazole and related compounds for the treatment of pain.Neuropathic pain is a debilitating consequence of spinal ...

Подробнее

Номер записи: 24

06-01-2022 дата публикации

XYLR Mutant For Improved Xylose Utilization Or Improved Co-Utilization Of Glucose And Xylose

Номер: US20220002356A1

Автор: CALLIHAN Isolde, DA COSTA Bernardo Moura Torres, FRYKMAN Scott Allen, PAYNE Stephen Thomas, VENKITESWARAN Sankaranarayanan, WONG Leland Ken

Принадлежит:

The disclosure relates to mutant gene(s) that confer upon microorganisms that express them an improved capacity to utilize xylose and improved capacity to co-utilize glucose and xylose thereby resulting in improved growth of the microorganism. Further encompassed are methods of producing fatty acids and fatty acid derivatives from cellulosic biomass, xylose, and/or a glucose/xylose mix by employing the host cells expressing the engineered XylR variants and compositions of biologically produced fatty acids and fatty acid derivatives. 1. A XylR protein variant , wherein the XylR protein variant has at least one mutation at a position selected from positions 83 , 88 , 89 , 112 , 120 , 141 , 145 , 146 , 147 , 150 , 154 , 155 , 247 , 270 , 280 , 286 , 289 , 295 , 305 , 306 , 313 , 333 , 336 , 337 , 351 , 364 , 365 , 372 , and 382 of SEQ ID NO: 1.2. A recombinant host cell comprising the XylR protein variant of .3. A method for increasing xylose utilization in a recombinant host cell claim 2 , the method comprising culturing in a culture medium comprising xylose claim 2 , the recombinant host cell of claim 2 , wherein expression of the XylR protein variant confers improved xylose utilization of the recombinant host cell in comparison to the xylose utilization of a host cell expressing SEQ ID NO: 1 when the cells are cultured in the presence of xylose.4. The method of claim 3 , wherein the method is used for preparing a fatty acid derivative claim 3 , the method comprising culturing in a culture medium comprising xylose claim 3 , a recombinant host cell which further comprises at least one heterologous fatty acid derivative biosynthetic enzyme.5. The method of claim 4 , wherein the fatty acid derivative is: a fatty acid ester and wherein at least one heterologous fatty acid derivative biosynthetic enzyme has ester synthase activity claim 4 , and optionally wherein at least one heterologous fatty acid derivative biosynthetic enzyme is a thioesterase; a ω-hydroxy fatty acid ...

Подробнее

Номер записи: 25

06-01-2022 дата публикации

MODULATION OF FORMATE OXIDATION BY RECOMBINANT YEAST HOST CELL DURING FERMENTATION

Номер: US20220002661A1

Автор: Argyros Aaron, Barrett Trisha, Skinner Ryan

Принадлежит:

The present disclosure concerns recombinant yeast host cells having a first genetic modification for increasing formate production, when compared to a corresponding native yeast host cell as well as a source of formate dehydrogenase activity. The source of formate can be an internal source of formate dehydrogenase activity and/or the recombinant yeast host call can be supplemented by an external source of formate dehydrogenase activity. 1. A recombinant yeast host cell having (i) a first genetic modification for increasing formate production , when compared to a corresponding native yeast host cell and (ii) a source of formate dehydrogenase activity , wherein the source of formate dehydrogenase activity is:an internal source of formate dehydrogenase activity provided by a second genetic modification; and/oran external source of formate dehydrogenase activity provided by a further yeast host cell having a third genetic modification.2. The recombinant yeast host cell of claim 1 , wherein the first genetic modification comprises introducing one or more first heterologous nucleic acid molecule encoding one or more polypeptide having pyruvate formate lyase activity in the recombinant yeast host cell.3. The recombinant yeast host cell of claim 2 , wherein the one or more polypeptide having pyruvate formate lyase activity comprises PFLA claim 2 , PFLB or a combination thereof.4Bifidobacterium. The recombinant yeast host cell of or claim 2 , wherein the one or more polypeptide having pyruvate formate lyase activity is from sp.5Bifidobacterium adolescentis.. The recombinant yeast host cell of claim 4 , wherein the one or more polypeptide having pyruvate formate lyase activity is from6. The recombinant yeast host cell of claim 5 , wherein the one or more polypeptide having pyruvate formate lyase activity comprises the amino acid sequence of SEQ ID NO: 6 claim 5 , is a variant of the amino acid sequence of SEQ ID NO: 6 having pyruvate formate lyase activity or is a fragment of ...

Подробнее

Номер записи: 26

06-01-2022 дата публикации

POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF

Номер: US20220002734A1

Автор: Hinkle Gregory

Принадлежит:

The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting the ALAS1 gene, and methods of using such agents to alter (e.g., inhibit) expression of ALAS1 and to treat ALAS1 associated diseases, e.g., porphyria. 1. (canceled)2. (canceled)3. A single-stranded antisense polynucleotide agent for inhibiting expression of aminolevulinic acid synthase-1 (ALAS1) , wherein the agent comprises at least 8 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences listed in Tables 3 and 4 , and wherein at least one of the contiguous nucleotides is a modified nucleotide.4. The agent of claim 3 , wherein substantially all of the nucleotides of the antisense polynucleotide agent are modified nucleotides.5. The agent of claim 3 , which is 10 to 40 nucleotides in length; 10 to 30 nucleotides in length; 18 to 30 nucleotides in length; or 10 to 24 nucleotides in length.6. The agent of claim 3 , wherein the modified nucleotide comprises a modified sugar moiety selected from the group consisting of: a 2′-O-methoxyethyl modified sugar moiety claim 3 , a 2′-methoxy modified sugar moiety claim 3 , a 2′-O-alkyl modified sugar moiety claim 3 , and a bicyclic sugar moiety.7. The agent of claim 3 , wherein the modified nucleotide is a 5-methylcytosine.8. The agent of claim 3 , wherein the modified nucleotide comprises a modified internucleoside linkage.9. The agent of claim 3 , comprising a plurality of 2′-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.10. The agent of claim 9 , wherein the agent is a gapmer comprising a gap segment comprised of linked 2′-deoxynucleotides positioned between a 5′ and a 3′ wing segment.11. The agent of claim 3 , comprisinga gap segment consisting of linked deoxynucleotides;a 5′-wing segment consisting of linked nucleotides;a 3′-wing segment consisting of linked nucleotides;wherein the gap segment is positioned between the 5′-wing ...

Подробнее

Номер записи: 27

06-01-2022 дата публикации

Bahd acyltransferases

Номер: US20220002744A1

Автор: Brian Fox, Craig Bingman, Emily Beebe, Faride Unda, Heather Mackay, Hoon Kim, John Ralph, Rebecca Anne Smith, Shawn Mansfield, Steven D. Karlen, Yaseen Mottiar

Принадлежит: University of British Columbia, WISCONSIN ALUMNI RESEARCH FOUNDATION

The invention is directed to BAHD acyltransferase enzymes, nucleic acids encoding BAHD acyltransferase enzymes, and inhibitory nucleic acids adapted to inhibit the expression and/or translation of BAHD acyltransferase RNA; expression cassettes, plant cells, and plants that have or encode such nucleic acids and enzymes; and methods of making and using such nucleic acids, enzymes, expression cassettes, cells, and plants.

Подробнее

Номер записи: 28

06-01-2022 дата публикации

MICROBIAL CELLS AND METHODS FOR PRODUCING CANNABINOIDS

Номер: US20220002764A1

Автор: Chen Lu, KUMARAN Ajikumar Parayil, PHILIPPE Ryan A., SANTOS Christine Nicole S.

Принадлежит:

Enzymes involved in cannabinoid biosynthesis are recombinantly expressed in a host cell. The host cell may be a prokaryote (e.g. ) or a eukaryote (e.g. ). The enzymes include a heterologous cannabigerolic acid synthase as well as additional enzymes involved in the biosynthesis of cannabinoid precursors such as geranyl diphosphate, olivetol, olivetolic acid, divarin and/or divarinic acid. Methods are provided for producing C5-cannabinoids and/or C3-cannabinoids by fermentation of the recombinant host cell. Alternatively, cannabinoids can be produced by biotransformation of cannabinoid precursors in recombinant cells or by disrupted recombinant cells. 1. A microbial cell for producing one or more cannabinoids , the microbial cell expressing a cannabinoid biosynthetic pathway comprising a heterologous prenyltransferase enzyme having cannabigerolic acid synthase (CBGAS) or cannabigerovarinic acid synthase (CBGVAS) activity ,the microbial cell further comprising one or more modifications that increases carbon flux to geranyl diphosphate (GPP) and/or carbon flux to one or more of hexanoic acid, hexanoyl-CoA, butyric acid, butyryl-CoA, and/or acetyl-CoA; and/orthe microbial cell produces the cannabinoid from one or more fed precursors selected from olivetol, olivetolic acid, divarin, divarinic acid, hexanoic acid, butyric acid, hexanoyl-CoA, butyryl-CoA, or derivative thereof and/or GPP precursor.2. The microbial cell of claim 1 , wherein the CBGAS or CBGVAS enzyme comprises the amino acid sequence of SEQ ID NO: 60 claim 1 , or a derivative thereof.3. The microbial cell of claim 1 , wherein the CBGAS or CBGVAS comprises an amino acid sequence selected from SEQ ID NO: 60 to 94 claim 1 , or a derivative thereof.4. The microbial cell of claim 3 , wherein the CBGAS comprises an amino acid sequence selected from: SEQ ID NOs: 63 claim 3 , 74 claim 3 , 77 claim 3 , 84-91 claim 3 , 93 and a derivative thereof.5. The microbial cell of claim 4 , wherein the derivative comprises the ...

Подробнее

Номер записи: 29

07-01-2016 дата публикации

Methods and Apparatus for Cell-Free Microfluidic-Assisted Biosynthesis

Номер: US20160002611A1

Автор: Gershenfeld Neil A., Mershin Andreas, Noireaux Vincent, Pelletier James Francis

Принадлежит:

A trans-disciplinary system for cell-free biosynthesis includes a cell-free transcription-translation (TX-TL) tool and modular, generalizable microfluidic architectures. Both components of the system are independently functional and are combinable into a cell-free biosynthesis platform. In the first component, modular plasmid libraries are used to program bacterial cell-free TX-TL systems. Each plasmid holds one gene or operon, and all the genes are controlled by the same promoter, so that the stoichiometry of enzyme synthesis is determined by the stoichiometry of plasmids in the reaction. In the second part, in order to facilitate high throughput mixing and matching of gene units from the modular plasmid libraries, a modular, reconfigurable, flexible, and scalable microfluidic architecture is employed. The microfluidic modules share common form factors and port/valve locations, so that a small set of module types, with multiple instances of each type interconnected in different geometries, allows simple reconfiguration to achieve different modes of operation. 1. A method for cell-free synthesis of a biosynthetic product , comprising the steps of: preparing a selected bacterial cell culture;', 'generating a cell extract from the bacterial cell culture;', 'combining the cell extract with amino acid and energy solutions to create a transcription-translation reaction buffer; and', 'separating reaction buffer aliquots by adding enzyme genes;, 'performing cell-free transcription-translation by the steps ofinfusing a microfluidic device with the reaction buffer aliquots, wherein the microfluidic device comprises one or more microfluidic modules configured for generating, controlling, and manipulating droplets of the reaction buffer aliquots;generating, controlling, and manipulating the droplets according to the configuration of the microfluidic device; andextracting droplets containing target molecules from the microfluidic device.2. The method of claim 1 , wherein the ...

Подробнее

Номер записи: 30

05-01-2017 дата публикации

MICROORGANISMS HAVING PUTRESCINE PRODUCTIVITY AND PROCESS FOR PRODUCING PUTRESCINE USING THE SAME

Номер: US20170002386A1

Автор: JUNG Hee Kyoung, KIM Chang Gyeom, LEE Baek Seok, Lee Kyoung Min, Lee Sun Young, LI Hong Xian, Park Su Jin, Um Hye Won, YANG Young Lyeol, YOON Jong Hyun

Принадлежит: CJ CHEILJEDANG CORPORATION

The present invention relates to a recombinant microorganism capable of producing putrescine, in which the microorganism is modified to have enhanced NCgl2522 activity, thereby producing putrescine in a high yield, and a method for producing putrescine using the microorganism. 1. A microorganism having putrescine productivity , which is modified to have enhanced activity of a protein having an amino acid sequence represented by SEQ ID NO: 21 or 23.2. The microorganism having putrescine productivity according to claim 1 , wherein the microorganism is further modified to have weakened activities of ornithine carbamoyltransferase (ArgF) and a protein (NCgl1221) involved in glutamate export claim 1 , compared to the endogenous activities claim 1 , and to have enhanced ornithine decarboxylase (ODC) activity.3. The microorganism having putrescine productivity according to claim 2 , wherein the ornithine carbamoyltransferase (ArgF) has an amino acid sequence represented by SEQ ID NO: 29 claim 2 , the protein (NCgl1221) involved in glutamate export has an amino acid sequence represented by SEQ ID NO: 30 claim 2 , and the ornithine decarboxylase (ODC) has an amino acid sequence represented by SEQ ID NO: 33.4. The microorganism having putrescine productivity according to claim 1 , wherein the microorganism is further modified to have enhanced activities of acetyl-gamma-glutamyl-phosphate reductase (ArgC) claim 1 , acetylglutamate synthase or ornithine acetyltransferase (ArgJ) claim 1 , acetylglutamate kinase (ArgB) claim 1 , and acetylornithine aminotransferase (ArgD) claim 1 , compared to the endogenous activities.5. The microorganism having putrescine productivity according to claim 4 , wherein the acetyl-gamma-glutamyl-phosphate reductase (ArgC) claim 4 , acetylglutamate synthase or ornithine acetyltransferase (ArgJ) claim 4 , acetyl glutamate kinase (ArgB) claim 4 , and acetylornithine aminotransferase (ArgD) have amino acid sequences represented by SEQ ID NOs: 25 claim 4 ...

Подробнее

Номер записи: 31

02-01-2020 дата публикации

MICROORGANISMS FOR PRODUCING PUTRESCINE OR ORNITHINE AND PROCESS FOR PRODUCING PUTRESCINE OR ORNITHINE USING THEM

Номер: US20200002686A1

Автор: JUNG Hee Kyoung, LEE Baek Seok, LEE Hyo Hyoung, Lee Kyoung Min, LI Hong Xian, Park Su Jin, Um Hye Won, YANG Young Lyeol

Принадлежит:

Disclosed is a modified microorganism producing putrescine or ornithine, and a method for producing putrescine or ornithine using the same. 115-. (canceled)16. A method for producing putrescine or ornithine , comprising:{'i': Corynebacterium', 'E. coli', 'E. coli, '(i) culturing a modified microorganism of the genus producing putrescine or ornithine in a medium, wherein activities of N-acetylglutamate synthase from and acetylornithine deacetylase from are introduced into the microorganism; and'}(ii) recovering putrescine or ornithine from the cultured microorganism or the medium.17CorynebacteriumCorynebacterium glutamicum.. The method according to claim 16 , wherein the microorganism of the genus is18E. coliE. coli. The method according to claim 16 , wherein the N-acetylglutamate synthase from consists of an amino acid sequence of SEQ ID NO: 1 claim 16 , and/or the acetylornithine deacetylase from consists of an amino acid sequence of SEQ ID NO: 3.19. The method according to claim 16 , wherein (a) an activity of phosphotransacetylase and acetate kinase operon (pta-ackA operon); (b) an activity of at least one selected from the group consisting of acetyl gamma glutamyl phosphate reductase (ArgC) claim 16 , acetylglutamate synthase or ornithine acetyltransferase (ArgJ) claim 16 , acetylglutamate kinase (ArgB) claim 16 , and acetyl ornithine aminotransferase (ArgD); and/or (c) an activity of putrescine exporter is further enhanced compared to its endogenous activity.20E. coli. The method according to claim 16 , wherein an activity of acetyl-CoA synthetase (acs) from claim 16 , and/or an activity of ornithine decarboxylase (ODC) is further introduced.21. The method according to claim 16 , wherein (a) an activity of i) ornithine carbamoyltransferase (ArgF) claim 16 , ii) glutamate exporter claim 16 , or iii) ornithine carbamoyltransferase and glutamate exporter and/or (b) an activity of acetyltransferase is further weakened compared to its endogenous activity. This ...

Подробнее

Номер записи: 32

04-01-2018 дата публикации

Synthetic carbon fixation pathways

Номер: US20180002704A1

Автор: Achuthanunni Chokkathukalam, Alex van Eck CONRADIE, Katherine Louise Tibbles, Ramdane Haddouche, Satnam Surae

Принадлежит: Invista North America LLC

The present disclosure relates to methods for more efficiently recycling reduced electron carriers in a hydrogen-oxidizing microorganism with an operable Calvin-Benson cycle; synthetic carbon fixation pathways that recycle reduced electron carriers more efficiently than the Calvin-Benson cycle, such as methods for enzymatically converting carbon dioxide to formate and assimilating the resulting formate into central carbon metabolism; methods for producing biochemical products; and recombinant hosts utilizing one or more synthetic carbon fixation pathways.

Подробнее

Номер записи: 33

04-01-2018 дата публикации

PRODUCTION OF MEVALONATE, ISOPRENE, AND ISOPRENOIDS USING GENES ENCODING POLYPEPTIDES HAVING THIOLASE, HMG-COA SYNTHASE AND HMG-COA REDUCTASE ENZYMATIC ACTIVITIES

Номер: US20180002727A1

Автор: Beck Zachary Q., Miller Michael C., PERES Caroline M., PRIMAK Yuliya A., PUCCI Jeff P., WELLS Derek H.

Принадлежит:

The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms via the heterologous expression of the mvaE and mvaS genes from the organisms DSM 20601, EG2, and 2. The cells of claim 1 , wherein the nucleic acids encoding polypeptides of the lower MVA pathway comprise enzymes selected from: (a) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (b) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (c) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.3M. mazeiM. burtoniiLactobacillusLactobacillus sakeiSaccharomyces cerevisiaeStreptococcusStreptococcus pneumoniaeStreptomycesStreptomyces. The cells of claim 1 , wherein the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is selected from the group consisting of mevalonate kinase claim 1 , mevalonate kinase polypeptide claim 1 , mevalonate kinase polypeptide claim 1 , mevalonate kinase polypeptide claim 1 , yeast mevalonate kinase polypeptide claim 1 , mevalonate kinase polypeptide claim 1 , mevalonate kinase polypeptide claim 1 , mevalonate kinase polypeptide claim 1 , mevalonate kinase polypeptide claim 1 , and CL190 mevalonate kinase polypeptide.4M. mazei. The cells of claim 3 , wherein the enzyme that phosphorylates mevalonate to mevalonate 5-phosphate is mevalonate kinase.5. The cells of claim 1 , wherein the isoprene synthase polypeptide is a plant isoprene synthase polypeptide or variants thereof.6PuerariaPopulusPopulus alba×Populus tremula. The cells of claim 5 , wherein the isoprene synthase polypeptide is a polypeptide from or or a hybrid claim 5 , claim 5 , or variants thereof.7Pueraria montana, Pueraria lobata, Populus tremuloides, Populus alba, Populus nigraPopulus trichocarpa.. The cells of claim 6 , wherein the isoprene synthase polypeptide is selected from the group consisting of claim 6 , and8Populus ...

Подробнее

Номер записи: 34

07-01-2021 дата публикации

COMPOSITIONS AND METHODS FOR TREATING CANCER

Номер: US20210002649A1

Автор: Lee Yu Ru, Pandolfi Pier Paolo, Wei Wenyi

Принадлежит: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

The invention generally provides a method of treating cancer, the method comprising administering to a subject having a cancer, an effective amount of an agent that inhibits the expression or activity of WW domain-containing protein-1 (WWP1) in combination with anti-PD-1 and/or anti-PD-L1 monoclonal antibodies. 1. A method of treating cancer in a selected subject , the method comprising administering to the subject an effective amount of an agent that inhibits the expression or activity of WWP1 and an anti-PD-1 and/or anti-PD-L1 antibody.2. A method of treating cancer in a subject , the method comprising administering to the subject an effective amount of an agent that inhibits the expression or activity of WWP1 and an anti-PD-1 and/or anti-PD-L1 antibody.3. A method of inhibiting the survival or proliferation of a neoplastic cell , the method comprising contacting the cell with an effective amount of an agent that inhibits the expression or activity of WWP1 and an anti-PD-1 and/or anti-PD-L1 antibody. thereby inhibiting the survival or proliferation of the neoplastic cell.4. The method of claim 1 , further comprising administering to the subject or the cell a NEDD4-1 inhibitor.5. The method of claim 1 , wherein the neoplastic cell is a mammalian cell.6. The method of claim 5 , wherein the mammalian cell is a murine claim 5 , rat claim 5 , or human cell.7. The method of claim 5 , wherein the cell is in vitro or in vivo.8. The method of claim 3 , wherein the neoplastic cell is a prostate cancer claim 3 , breast cancer claim 3 , or colorectal cancer cell.9. The method of claim 1 , wherein the subject has prostate cancer claim 1 , breast cancer claim 1 , or colorectal cancer.10. The method of claim 1 , wherein the agent is a polypeptide claim 1 , polynucleotide claim 1 , or a small molecule.11. The method of claim 10 , wherein the polynucleotide is an inhibitory nucleic acid molecule that inhibits the expression of WWP1.12. The method of claim 11 , wherein the ...

Подробнее

Номер записи: 35

03-01-2019 дата публикации

BIOSYNTHESIS OF POLYKETIDES

Номер: US20190002848A1

Автор: CHEONG Seokjung, CLOMBURG James M., GONZALEZ Ramon

Принадлежит:

This disclosure generally relates to the use of microorganisms to make various functionalized polyketides through polyketoacyl-CoA thiolase-catalyzed non-decarboxylative condensation reactions instead of decarboxylative reactions catalyzed by polyketide synthases. Native or engineered polyketoacyl-CoA thiolases catalyze the non-decarboxylative Claisen condensation in an iterative manner (i.e. multiple rounds) between two either unsubstituted or functionalized ketoacyl-CoAs (and polyketoacyl-CoAs) serving as the primers and acyl-CoAs serving as the extender unit to generate (and elongate) polyketoacyl-CoAs. Before the next round of polyketoacyl-CoA thiolase reaction, the β-keto group of the polyketide chain of polyketoacyl-CoA can be reduced and modified step-wise by 3-OH-polyketoacyl-CoA dehydrogenase or polyketoenoyl-CoA hydratase or polyketoenoyl-CoA reductase. Dehydrogenase converts the β-keto group to β-hydroxy group. Hydratase converts the β-hydroxy group to α-β-double-bond. Reductase converts the α-β-double-bond to single bond. Spontaneous or thioesterase catalyzed termination reaction terminates the elongation of polyketide chain of polyketoacyl-CoA at any point through CoA removal and spontaneous reactions rearrange the structure, generating the final functional polyketide products. 133-. (canceled)34) A method of making a polyketide , comprising growing a genetically engineered microorganism in a nutrient broth for a time sufficient to produce a polyketide and isolating said polyketide or a spontaneously rearranged form of said polyketide or a derivative of said polyketide , wherein said microorganism has a polyketide-producing pathway comprising the following substrate(s) to product(s) conversions:a) C(n)-acyl-CoA+acetyl-CoA→C(n+2)-ketoacyl-CoA;b) C(n+2)-ketoacyl-CoA+acetyl-CoA→C(n+4)-polyketoacyl-CoA;c) optionally, C(n+4)-polyketoacyl-CoA→3-OH—C(n+4)-polyketoacyl-CoA;d) optionally, 3-OH—C(n+4)-polyketoacyl-CoA→C(n+4)-polyketoenoyl-CoA; ande) optionally, C ...

Подробнее

Номер записи: 36

03-01-2019 дата публикации

METHODS, MATERIALS, SYNTHETIC HOSTS AND REAGENTS FOR THE BIOSYNTHESIS OF HYDROCARBONS AND DERIVATIVES THEREOF

Номер: US20190002926A1

Автор: Cartman Stephen Thomas, Combe Jonathan Paul, Pattenden Leonard Keith, Shaw Andrew, Zampini Massimiliano

Принадлежит: INVISTA North America S.a.r.l.

Genetically engineered hosts and methods for their production and use in synthesizing hydrocarbons are provided. 1: A genetically engineered host capable of producing hydrocarbons via a mevalonate (MVA) pathway.3: The genetically engineered host of comprising at least one genome-integrated synthetic operon encoding an enzyme of the MVA pathway.4: The genetically engineered host of comprising a genome-integrated synthetic operon encoding a plurality of enzymes of the MVA pathway.5: The genetically engineered host of encoding one or more enzymes selected from acetoacetyl-CoA C-acetyltransferase (AACT) claim 1 , HMG-CoA reductase (HMGR) claim 1 , hydroxymethylglutaryl-CoA synthase (HMGS) claim 1 , mevalonate kinase (MVK) claim 1 , phosphomevalonate kinase (MPK0 claim 1 , mevalonate diphosphate decarboxylase (MDD) claim 1 , isopentenyl diphosphate isomerase (IDI) and isoprene synthase (ISPS).6: The genetically engineered host of comprising a genome-integrated synthetic operon encoding one or more of enzymes of the upper MVA pathway.7Enterococcus faecalis: The genetically engineered host of comprising a genome-integrated synthetic operon encoding one or more of the enzymes of the upper MVA pathway.8: The genetically engineered host of comprising an exogenous nucleic acid sequence encoding a polypeptide having AACT claim 6 , HMGR or HGMS enzyme activity.9: The genetically engineered host of wherein the polypeptide having AACT claim 8 , HMGR or HGMS enzyme activity:(i) has at least 70% sequence identity to an amino acid sequence set forth in SEQ ID NO: 1, 56, 58, 60, 62, 64 66, 2, 68, 70, 72 or 74 or a functional fragment thereof;(ii) comprises an amino acid sequence set forth in SEQ ID NO: 1, 56, 58, 60, 62, 64 66, 2, 68, 70, 72 or 74 or a functional fragment thereof;(iii) has at least 70% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 23, 55, 57, 59, 61, 63, 65, 24, 67, 69, 71 or 73 or a functional fragment thereof; or(iv) comprises SEQ ID NO: 23, ...

Подробнее

Номер записи: 37

03-01-2019 дата публикации

TAILORED OILS

Номер: US20190002934A1

Автор: Bhat Riyaz, Franklin Scott, Moseley Jeffrey L., Rudenko George, Somanchi Aravind, ZHAO Xinhua

Принадлежит:

Recombinant DNA techniques are used to produce oleaginous recombinant cells that produce triglyceride oils having desired fatty acid profiles and regiospecific or stereospecific profiles. Genes manipulated include those encoding stearoyl-ACP desaturase, delta 12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase. The oil produced can have enhanced oxidative or thermal stability, or can be useful as a frying oil, shortening, roll-in shortening, tempering fat, cocoa butter replacement, as a lubricant, or as a feedstock for various chemical processes. The fatty acid profile can be enriched in midchain profiles or the oil can be enriched in triglycerides of the saturated-unsaturated-saturated type. 184.-. (canceled)85ProtothecaChlorella,. A recombinant cell of the genus or said recombinant cell comprising a knockout or knockdown of an endogenous Fatty acyl-ACP thioesterase gene , and further comprising exogenous nucleic acids that encode lysophosphatidic acid acyltransferase (LPAAT).86. The recombinant cell of claim 85 , wherein said exogenous nucleic acids that encode LPAAT encodes an LPPAT having at least 90% amino acid sequence identity to an LPAAT selected from the group consisting of SEQ ID NOs: 16 claim 85 , 77 claim 85 , 78 claim 85 , 79 and 157.87. The recombinant cell of claim 86 , wherein said exogenous nucleic acids that encode LPAAT encodes an LPPAT having at least 95% amino acid sequence identity to an LPAAT selected from the group consisting of SEQ ID NOs: 16 claim 86 , 77 claim 86 , 78 claim 86 , 79 and 157.88. The recombinant cell of claim of claim 86 , wherein said exogenous nucleic acids encodes an LPAAT comprising the amino acid sequences of SEQ ID NO: 157.89. The recombinant cell of claim of claim 86 , wherein said exogenous nucleic acids encodes an LPAAT comprising the amino acid sequences of SEQ ID NOs: 17 claim 86 , 77 claim 86 , 78 or 79.90. The recombinant cell of claim 89 , wherein ...

Подробнее

Номер записи: 38

20-01-2022 дата публикации

RECOMBINANT MICROORGANISM CAPABLE OF GROWING USING ONLY CARBON DIOXIDE AND FORMIC ACID AND METHOD FOR PRODUCING USEFUL SUBSTANCES USING THE RECOMBINANT MICROORGANISM

Номер: US20220017879A1

Автор: Ahn Jung Ho, BANG Junho, HWANG Chang Hun, LEE Jong An, LEE Sang Yup

Принадлежит:

Disclosed is a recombinant microorganism capable of growing using only carbon dioxide and formic acid by introducing and improving a metabolic pathway for synthesizing pyruvic acid from carbon dioxide and formic acid to enhance pyruvic acid synthesis efficiency and performing additional genetic manipulation, and a method for producing useful substances using the same. Advantageously, the recombinant microorganism is capable of synthesizing pyruvic acid, a C3 organic compound, at a remarkably improved rate, and in particular, grows well even in a medium containing only carbon dioxide and formic acid as carbon sources without a glucose supply, and is thereby capable of synthesizing pyruvic acid and various high value-added compounds using the same as an intermediate product in an economically efficient manner. 1. A recombinant microorganism , in which a gene encoding a glycine cleavage system transcriptional repressor , pyruvate formate lyase , or phosphoglycerate dehydrogenase is attenuated or deleted from a host microorganism having a formic acid assimilation pathway ,a gene encoding an enzyme involved in a glycine cleavage system reaction is enhancely expressed in the host microorganism having the formic acid assimilation pathway, anda gene encoding formate-tetrahydrofolate ligase, methenyl tetrahydrofolate cyclohydrolase, or methylene-tetrahydrofolate dehydrogenase is introduced into the host microorganism having the formic acid assimilation pathway.2Escherichia, Mannheimia, RhodobacterMethylobacterium. The recombinant microorganism according to claim 1 , wherein the host microorganism is selected from the group consisting of and genera.3. The recombinant microorganism according to claim 1 , wherein the expression of the gene encoding the enzyme involved in the glycine cleavage system reaction is enhanced by substituting a native promoter with a strong promoter.4. The recombinant microorganism according to claim 3 , wherein the strong promoter is selected from the ...

Подробнее

Номер записи: 39

12-01-2017 дата публикации

HEMOSTATIC COMPOSITIONS AND METHODS

Номер: US20170007742A1

Автор: BEALL Dawson, BRICHETTI Jennifer, MACPHEE Martin, WILMER Belinda

Принадлежит: STB, Ltd.

Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A composition for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic putty that is formed by combining a hemostatic material in an aqueous solution and drying under certain conditions to form a putty material that is capable of forming fibrin when in contact with an aqueous solution.2. The composition in claim 1 , wherein said composition is substantially non-adherent to latex gloves.3. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue the haemostatic putty of .4. A composition for treating wounded internal tissue in a mammal comprising at least one haemostatic material made by compressing powdered hemostatic components together with excipients to form shaped haemostatic materials.5. The composition of claim 4 , wherein said powdered hemostatic components are made from a single aqueous solution.6. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue the haemostatic composition of .7. The composition of claim 1 , wherein said hemostatic material consists essentially of a fibrinogen component and a fibrinogen activator.8. The composition of claim 1 , wherein said hemostatic material consists essentially of a fibrinogen component.9. The composition of claim 1 , wherein said hemostatic material consists essentially of a fibrinogen activator.10. The composition of claim 4 , wherein said hemostatic material consists essentially of a fibrinogen component and a fibrinogen activator.11. The composition of claim 4 ...

Подробнее

Номер записи: 40

11-01-2018 дата публикации

Cleavable Lipids

Номер: US20180008543A1

Автор: DeRosa Frank, GUILD Braydon Charles, Heartlein Michael, Zhang Jerry Chi

Принадлежит:

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent iransfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids. 2. (canceled)3. The nanoparticle of claim 1 , wherein Ris imidazole.4. The nanoparticle of claim 1 , wherein{'sub': '1', 'Ris imidazole;'}andn is 1.5. The nanoparticle of claim 1 , wherein Ris guanidinium.6. The nanoparticle-of claim 1 , wherein{'sub': '1', 'Ris guanidinium;'}andn is 1.723.-. (canceled)2629.-. (canceled)30. The nanoparticle of claim 1 , further comprising one or more compounds selected from the group consisting of a cationic lipid claim 1 , a PEG-modified lipid claim 1 , a non-cationic lipid and a helper lipid.31. (canceled)32. The nanoparticle of claim 1 , wherein one or more of the polynucleotides comprises a chemical modification.33. The nanoparticle of claim 1 , wherein the one or more polynucleotides is selected from the group consisting of an antisense oligonucleotide claim 1 , siRNA claim 1 , miRNA claim 1 , snRNA claim 1 , snoRNA and combinations thereof.34. (canceled)35. The nanoparticle of claim 1 , wherein the one or more polynucleotides comprise DNA.36. The nanoparticle of claim 1 , wherein the one or more polynucleotides comprise RNA.37. (canceled)38. The nanoparticle of claim 36 , wherein the RNA encodes an enzyme.39. The nanoparticle of claim 38 , wherein the enzyme is selected from the group consisting of agalsidase alfa claim 38 , alpha-L-iduronidase claim 38 , iduronate-2-sulfatase claim 38 , N-acetylglucosamine-1-phosphate transferase claim 38 , N-acetylglucosaminidase claim 38 , alpha-glucosaminide acetyltransferase claim 38 , N- ...

Подробнее

Номер записи: 41

12-01-2017 дата публикации

VECTORS AND STRAINS FOR PRODUCING MYRCENE AND METHOD OF PRODUCING MYRCENE USING THE SAME

Номер: US20170009240A1

Автор: GONG Gyeongtaek, KIM Eun Mi, KIM Yunje, Lee Sun Mi, UM Youngsoon, WOO Han Min

Принадлежит: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Disclosed herein are an expression vector capable of expressing myrcene, an strain transformed with the vector and having improved capability of producing myrcene and a method for producing myrcene and a method for recycling glycerol using the same. In an aspect, the transformed strain of the present disclosure can produce myrcene with high purity on a large scale using glycerol or glucose as a carbon source. Also, the strain of the present disclosure is economical and environment-friendly because it can produce high value-added myrcene using waste glycerol as a carbon source. In addition, the strongly volatile myrcene can be produced and isolated at the same time. 1Escherichia coli. A transformed strain transformed with a first vector and a second vector ,the first vector comprising, in sequence,a chloramphenicol resistance gene as a selection marker;a p15A replication origin as a replication origin;a lacUV5 promoter;a first domain comprising a gene encoding an enzyme which produces mevalonate from acetyl-CoA; anda second domain comprising a gene encoding an enzyme which produces dimethylallyl pyrophosphate (DMAPP) from mevalonate, andthe second vector comprising, in sequence,an ampicillin resistance gene as a selection marker;a ColE1 replication origin as a replication origin;a trc promoter; anda gene encoding an enzyme which is capable of producing myrcene from geranyl pyrophosphate (GPP).2Escherichia coli. The transformed strain according to claim 1 ,wherein the first vector further comprises one or more selected from a trc promoter; and a gene encoding an enzyme which is capable of producing geranyl pyrophosphate (GPP) from dimethylallyl pyrophosphate (DMAPP) and isopentenyl diphosphate (IPP),the trc promoter is located between the first domain and the second domain, andthe gene encoding an enzyme which is capable of producing geranyl pyrophosphate (GPP) from dimethylallyl pyrophosphate (DMAPP) and isopentenyl diphosphate (IPP) is located downstream of the ...

Подробнее

Номер записи: 42

14-01-2016 дата публикации

Novel Ketoacyl ACP Synthase Genes and Uses Thereof

Номер: US20160010066A1

Автор: Casolari Jason, Davis David, Ewing Aren, Franklin Scott, Rudenko George, Somanchi Aravind

Принадлежит:

The present invention relates to beta-ketoacyl ACP synthase genes of the KASI/KASIV type and proteins encoded by these genes. The genes can be included in nucleic acid constructs, vectors or host cells. Expression of the gene products can alter the fatty acid profile of host cells. The KAS genes can be combined with a FATA or FATB thioesterase gene to create a cell that produces an increased amount of C8-C16 fatty acids. Suitable host cells include plastidic cells of plants or microalgae. Oleaginous microalga host cells with the new genes are disclosed. 1. A non-natural , isolated polynucleotide having at least 80 , 85 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99% sequence identity or equivalent sequence by virtue of the degeneracy of the genetic code to any one of SEQ ID NOs: 21-37 , or 39-55 , or encoding a KASI-like protein having at least 80 , 85 , 85.5 , 86 , 86.5 , 87 , 87.5 , 88 , 88.5 , 89 , 89.5 , 90 , 90.5 , 91 , 91.5 , 92 , 92.5 , 93 , 93.5 , 94 , 94.5 , 95 , 95.5 , 96 , 96.5 , 97 , 97.5 , 98 , 98.5 , 99 or 99.5% amino acid sequence identity to any one of SEQ ID NOs: 2-18 , 62-72 , or a mature protein produced therefrom , or the complement of the polynucleotide.2. A transformation vector comprising the cDNA of .3. The vector of claim 2 , comprising promoter and 3′UTR sequences in operable linkage to the cDNA claim 2 , and optionally a flanking sequence for homologous recombination.4. A host cell comprising the vector of .5. The host cell of claim 4 , wherein the host cell is a plastidic oleaginous cell having a type II fatty acid biosynthesis pathway.6. The host cell of claim 5 , wherein the host cell is a microalga.7ChlorellaPrototheca.. The host cell of claim 6 , wherein the host cell is of Trebouxiophyceae claim 6 , and optionally of the genus or8Prototheca moriformis.. The host cell of claim 7 , wherein the microalga is of the species9. A method for making a cell-oil claim 4 , the method comprising cultivating a host cell of claim 4 , so as ...

Подробнее

Номер записи: 43

14-01-2016 дата публикации

Modified native beta-ketoacyl-acp synthases and engineered microorganisms

Номер: US20160010115A1

Автор: Catherine M. Cho, Fernando Valle, Jonathan VROOM, Louis Clark, Robert Osborne, Smita Shankar

Принадлежит: Codexis Inc

Genetically engineered cells and microorganisms are provided that produce fatty alcohols and fatty acids. In particular, engineered microbial cells comprise a modified native gene having β-ketoacyl-acp synthase activity.

Подробнее

Номер записи: 44

14-01-2021 дата публикации

CELLULAR TRANSPORT SYSTEM FOR TRANSFERRING A SULFONIC ACID CONSTRUCT CARRYING A CARGO INTO THE CYTOPLASM OF A CELL

Номер: US20210009513A1

Автор: KÜNZL Tilmann, Marliere Philippe, PANKE Sven

Принадлежит:

The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfonate transporter located in the cytoplasm membrane of the cell wherein said sulfonate transporter is capable of transporting said sulfonic acid construct across the cytoplasm membrane into the cytoplasm; (ii) a γ-glutamyl transferase (GGT; EC 2.3.2.2) which is modified to be located in the cytoplasm of the cell, wherein said γ-glutamyl transferase is capable of hydrolyzing said sulfonic acid construct so as to release the cargo. Moreover, the present invention relates to the use of a cellular transport system for bringing a sulfonic acid construct which contains a cargo into a cell and releasing the cargo in the cell's cytoplasm. Further, the present invention relates to a γ-glutamyl transferase for hydrolyzing a sulfonic acid construct which contains a cargo. 2. The cellular transport system according to claim 1 , wherein Lis —(CH)— and wherein Lis —C(═O)—.3. The cellular transport system according to claim 1 , wherein the γ-glutamyl transferase (GGT) is modified to be located in the cytoplasm of the cell by a signal-peptide truncation.4. The cellular transport system according to claim 1 , wherein the γ-glutamyl transferase (GGT) has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence having at least 30% sequence identity to SEQ ID NO:1 and lacking at least 16 N-terminal amino acids claim 1 , wherein the enzymatically active form of said γ-glutamyl transferase is capable of hydrolyzing said sulfonic acid construct of formula (I) to release the compound H—X.5E. coli.. The cellular transport system according to claim 1 , wherein the sulfonate transporter located in the cytoplasm membrane of the cell is a TauABC transporter or an SsuABC transporter derived from6E. coli. The cellular transport system according to ...

Подробнее

Номер записи: 45

11-01-2018 дата публикации

PRODUCTION OF FATTY ACID DERIVATIVES

Номер: US20180010137A1

Автор: Clarke Elizabeth J., Da Costa Bernardo M., Greenfield Derek L., Groban Eli S., HELMAN Noah, Holden Kevin, HU Zhihao, Schirmer Andreas W.

Принадлежит:

The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, recombinant host cells and recombinant host cell cultures engineered to produce fatty acid derivative compositions comprising fatty acids, fatty alcohols, fatty aldehydes, fatty esters, alkanes, terminal olefins, internal olefins or ketones. The fatty acid derivative composition is produced extracellularly with a higher titer, yield or productivity than the corresponding wild type or non-engineered host cell. 151.-. (canceled)52. A recombinant host cell comprising a decreased activity of a phosphoenolpyruvate carboxylase (ppc) polypeptide , wherein said recombinant host cell produces a fatty acid derivative composition at a higher titer , yield or productivity than a corresponding wild type host cell when cultured in a medium containing a carbon source under conditions effective to decrease expression of said ppc polypeptide.53. A cell culture comprising the recombinant host cell according to .54. The cell culture of claim 52 , wherein said cell culture comprises a fatty acid derivative composition.55. The cell culture of claim 54 , wherein the fatty acid derivative composition comprises at least one fatty acid derivative selected from the group consisting of fatty acid claim 54 , a fatty ester claim 54 , a fatty alcohol claim 54 , a fatty aldehyde claim 54 , an alkane claim 54 , a terminal olefin claim 54 , an internal olefin claim 54 , and a ketone.56. The cell culture of claim 53 , wherein the fatty acid derivative isa) a C6, C8, C10, C12, C13, C14, C15, C16, C17, or C18 fatty acid derivative, orb) a C10:1, C12:1, C14:1, C16:1, or C18:1 unsaturated fatty acid derivative.57. The cell culture of claim 54 , wherein the fatty acid derivative composition comprises:a) one or more of C8, C10, C12, C14, C16, and C18 fatty acid derivatives,b) fatty acids,c) fatty aldehydes,d) fatty alcohols,e) fatty esters,f) alkanes,g) terminal olefins,h) internal olefins, ori) ...

Подробнее

Номер записи: 46

11-01-2018 дата публикации

MICROBIAL PRODUCTION OF N-BUTYRALDEHYDE

Номер: US20180010155A1

Автор: Cho Kwang Myung, HIGASHIDE Wendy, Lee Chrissie, RABIZADEH Shahrooz

Принадлежит: Easel Biotechnologies, LLC

Microorganisms and methods of producing n-butyraldehyde with enhanced yields are presented in which a microorganism is engineered to enhance the conversion of a carbon source into n-butyraldehyde. The n-butyraldehyde is recovered by way of a gas stripping process that occurs during the conversion process, providing significantly greater product yield than post-fermentation recovery of n-butyraldehyde alone. 2. The microorganism of claim 1 , wherein the acetyl-CoA acetyltransferase has an E.C. number of 2.3.1.9.3. The microorganism of claim 1 , wherein the 3-hydroxyacyl-CoA dehydrogenase has an E.C. number of 1.1.1.157.4. The microorganism of claim 1 , wherein the crotonyl-CoA hydratase has an E.C. number of 4.2.1.55.5. The microorganism of claim 1 , wherein the butyryl-CoA dehydrogenase has an E.C. number of 1.3.99.2.6. The microorganism of claim 1 , wherein the trans-enoyl-CoA reductase has an E.C. number of 1.3.1.38.7. The microorganism of claim 1 , wherein the butanal dehydrogenase has an E.C. number of 1.2.1.57.8. The microorganism of claim 1 , wherein the at least one native gene is selected from the group consisting of ldhA claim 1 , adhE claim 1 , frdBC claim 1 , pta claim 1 , and yqhD.9. The microorganism of claim 1 , wherein the at least one native gene are ldhA claim 1 , adhE claim 1 , and frdBC.10. The microorganism of claim 1 , wherein the at least one native gene are ldhA claim 1 , adhE claim 1 , frdBC claim 1 , pta claim 1 , and yqhD.11. The microorganism of claim 1 , wherein at least one native gene is deleted to reduce alcohol production by at least 70%.12. The microorganism of claim 1 , wherein at least one native gene is deleted to reduce alcohol production by at least 90%.13. The microorganism of claim 1 , wherein the genetically modified microorganism produces a cumulative yield of 2.0 g/L n-butyraldehyde at or before 40 hours of culture time.14. The microorganism of claim 1 , wherein the genetically modified microorganism produces 50% of a ...

Подробнее

Номер записи: 47

11-01-2018 дата публикации

ENGINEERED STRAIN OF ESCHERICHIA COLI FOR PRODUCTION OF POLY-R-3-HYDROXYALKANOATE POLYMERS WITH DEFINED MONOMER UNIT COMPOSITION AND METHODS BASED THEREON

Номер: US20180010156A1

Автор: Nomura Christopher T., Tappel Ryan C., Wang Qin

Принадлежит:

Methods and systems for producing prescribed unit size poly(3-hydroxyalkanoate) (PHA) polymers and copolymers are provided. The methods and systems can employ recombinant bacteria that are not native producers of PHA or lack enzymes to degrade PHA once synthesized, metabolize short to long chain fatty acids without induction, and express an (R)-specific enoyl-CoA hydratase and a PHA synthase, the (R)-specific enoyl-CoA hydratase and PHA synthase having wide substrate specificities. The recombinant bacteria are fed at least one fatty acid substrate that is equal in carbon length to the prescribed or desired unit size of the PHA polymer to be produced. The prescribed unit size PHA that is produced is then isolated and/or purified. 1. A recombinant bacterium for producing a prescribed unit size of PHA polymer , wherein the bacterium:metabolizes a short to long chain fatty acid substrate without induction,expresses an (R)-specific enoyl-CoA hydratase and a PHA synthase, andproduces exclusively a prescribed unit size poly(3-hydroxyalkanoate) (PHA) polymer from at least one fatty acid substrate, the at least one fatty acid substrate being of equal carbon length to the prescribed unit size of the PHA polymer to be produced.2. The recombinant bacterium of claim 1 , wherein the bacterium is not a native or natural producer of PHA or lacks enzymes to degrade PHA once synthesized.3E. coli.. The recombinant bacterium of claim 1 , wherein the recombinant bacterium is a recombinant4. The recombinant bacterium of claim 1 , wherein the bacterium comprises a plasmid comprising an (R)-specific enoyl-CoA hydratase gene and a PHA synthase gene.5. The recombinant bacterium of claim 1 , wherein β-oxidation is blocked in the recombinant bacterium.6. The recombinant bacterium of claim 1 , wherein at least one gene encoding an enzyme for β-oxidation is inactive or deleted from the chromosome of the recombinant bacterium.7. The recombinant bacterium of claim 1 , wherein the recombinant ...

Подробнее

Номер записи: 48

10-01-2019 дата публикации

Method of Producing Lipid

Номер: US20190010525A1

Автор: Shinji Sugihara, Tatsuro Ozaki

Принадлежит: Kao Corp

A method of producing lipids, containing the steps of: culturing a transformant in which the expression of a gene encoding the following protein (A) or (B) is enhanced, and producing long-chain fatty acids or the lipids containing these fatty acids as components, wherein: protein (A) is a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1; and protein (B) is a protein consisting of an amino acid sequence having 70% or more identity with the amino acid sequence of the protein (A), and having β-ketoacyl-ACP synthase activity.

Подробнее

Номер записи: 49

11-01-2018 дата публикации

HUMAN FACTOR XIII AS A NORMALIZATION CONTROL FOR IMMUNOASSAYS

Номер: US20180011093A1

Автор: del Rosario Renato, KING David, Leos Michael, Link William F.

Принадлежит:

The present disclosure provides compositions and methods that are useful for normalizing the amount of signal detected in an assay, such as an immunoassay. The compositions and methods are useful for improving the accuracy of immunoassays, such as immunoassays that detect whether a subject is infected with a retrovirus such as HIV. 1. A kit for correcting for variations in sample processing and/or biological matrix effects when performing biological assays , said kit comprising a normalization factor immobilized on a solid support.2. The kit of claim 1 , wherein the normalization factor does not bind an analyte from a biological sample.3. The kit of claim 1 , wherein the normalization factor is hFXIII.4. The kit of claim 1 , further comprising an antibody to human Factor XIII immobilized on a solid support.5. The kit of claim 1 , further comprising tetramethylcadaverine rhodamine (TMRC) immobilized on a solid support.6. The kit of claim 1 , wherein the solid support is a bead or magnetic bead.7. The kit of claim 1 , further comprising a plurality of solid supports having binding members immobilize thereon that bind one or more analytes in a sample.8. The kit of claim 7 , wherein the plurality of solid supports are divided into subpopulations that are differentiable from each other by a differentiation parameter comprising a characteristic that is independent of the binding members immobilized on the solid supports claim 7 , the binding members immobilized on each subpopulation capable of binding to one analyte in the sample.9. A composition for correcting for variations in sample processing and/or biological matrix effects when performing biological assays claim 7 , said composition comprising a normalization factor coupled to a solid support.10. The composition of claim 9 , wherein the normalization factor does not bind an analyte from a biological sample.11. The composition of claim 9 , wherein the normalization factor is hFXIII.12. The composition of claim 9 , ...

Подробнее

Номер записи: 50

09-01-2020 дата публикации

Genetically Altered Alfalfa Producing Clovamide and/or Related Hydroxycinnamoyl Amides

Номер: US20200010843A1

Автор: Sullivan Michael L.

Принадлежит:

Two novel cDNAs for two different genes, HDT1 and HDT2, are isolated from red clover and sequenced. Both HDT1 and HDT2 encode hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase (HDT) which enzymatically produces clovamide and/or related hydroxycinnamoyl amides. Clovamide and related hydroxycinnamoyl amides reduce post-harvest protein degradation. Genetically altered alfalfa plants containing an expression cassette containing a cDNA encoding HDT1 or HDT2 are generated. These genetically altered alfalfa plants produce hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase, which in turn produces clovamide and/or related hydroxycinnamoyl amides. 126-. (canceled)27. A cDNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 3 , a sequence that is at least 95% identical to SEQ ID NO: 1 , and a sequence that is at least 95% identical to SEQ ID NO: 3 , wherein said cDNA encodes a protein with hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase activity.28. An expression cassette comprising a heterologous promoter operably linked to said cDNA of .29. A cDNA that encodes a hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase comprising a nucleotide sequence that encodes a hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase wherein said hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase has an amino acid sequence selected from the group consisting of SEQ ID NO: 2 claim 27 , SEQ ID NO: 4 claim 27 , a sequence that is at least 95% identical to SEQ ID NO: 2 claim 27 , and a sequence that is at least 95% identical to SEQ ID NO: 4.30. An expression cassette comprising a heterologous promoter operably linked to said cDNA of .31. A kit for determining if an alfalfa plant contains HDT1 or HDT2 gene and thereby produces a hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase claim 29 , said kit comprising at least one pair of polynucleotides; an ...

Подробнее

Номер записи: 51

09-01-2020 дата публикации

METHOD FOR THE PRODUCTION OF ISOAMYL ALCOHOL

Номер: US20200010858A1

Автор: Allard Mathieu, Anissimova Maria

Принадлежит: Global Bioenergies

Described is a method for the production isoamyl alcohol (3-methylbutan-1-ol) comprising the enzymatic conversion of 3-methylbutyryl-CoA (isovaleryl-CoA) into isoamyl alcohol comprising: (a) two enzymatic steps comprising (i) first the enzymatic conversion of 3-methylbutyryl-CoA into 3-methylbutyraldehyde (3-methylbutanal or isovaleraldehyde); and (ii) then enzymatically converting the thus obtained 3-methylbutyraldehyde into said isoamyl alcohol; or (b) a single enzymatic reaction in which 3-methylbutyryl-CoA is directly converted into isoamyl alcohol by making use of an alcohol-forming short chain acyl-CoA dehydrogenase/fatty acyl-CoA reductase or an alcohol-forming fatty acyl-CoA reductase (long-chain acyl-CoA:NADPH reductase) (EC 1.2.1.84). Further, described is the above method wherein the 3-methylbutyryl-CoA can be provided by the enzymatic conversion of 3-methylcrotonyl-CoA into said 3-methylbutyryl-CoA. It is also described that the thus obtained isoamyl alcohol can be further enzymatically converted into 3-methylbutyl acetate (isoamyl acetate) as described herein. Described are also recombinant organisms or microorganisms which are capable of performing the above enzymatic conversions. Furthermore, described are uses of enzymes and enzyme combinations which allow the above enzymatic conversions. 1. A method for the production of isoamyl alcohol (3-methylbutan-1-ol) comprising the enzymatic conversion of 3-methylbutyryl-CoA into isoamyl alcohol comprising: (i) first the enzymatic conversion of 3-methylbutyryl-CoA into 3-methylbutyraldehyde; and', '(ii) then enzymatically converting the thus obtained 3-methylbutyraldehyde into said isoamyl alcohol; or, '(a) two enzymatic steps comprising'}(b) a single enzymatic reaction in which 3-methylbutyryl-CoA is directly converted into isoamyl alcohol by making use of an alcohol-forming short chain acyl-CoA dehydrogenase/fatty acyl-CoA reductase or an alcohol-forming fatty acyl-CoA reductase (long-chain acyl-CoA:NADPH ...

Подробнее

Номер записи: 52

03-02-2022 дата публикации

Vegan fermented soft cheese

Номер: US20220030899A1

Автор: Alice CIBRARIO, Fabien Durand, Virginie PADEL

Принадлежит: SAVENCIA SA

The present invention relates to a food product composed of vegetable ingredients having visual, textural and flavour properties of a soft fermented cheese.

Подробнее

Номер записи: 53

03-02-2022 дата публикации

Provision of malonyl-coa in coryneform bacteria and method for producing polyphenoles and polyketides with coryneform bacteria

Номер: US20220033786A1

Автор: Jan Marienhagen, Lars Milke, Michael Bott, Nicolai Kallscheuer

Принадлежит: FORSCHUNGSZENTRUM JUELICH GMBH

A coryneform bacteria cell with an increased provision of Malonyl-CoA compared to its archetype, wherein the regulation and/or expression of one or more of genes fasB, gltA, accBC and accD1, and/or the functionality of the enzyme encoded by each gene is modified in a targeted manner. The cell may have one or more targeted modifications, including reduced or eliminated functionality of the fatty acid synthase FasB, mutation or partial or complete deletion of the fatty acid synthase encoding gene fasB, and/or reduced functionality of the promoter operatively linked to the citrate synthase gene gtIA, among other targeted modifications.

Подробнее

Номер записи: 54

03-02-2022 дата публикации

ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF 2-OXOADIPATE BY FERMENTATION

Номер: US20220033862A1

Автор: Chowdhury Anupam, Edgar Steven M., Shearer Alexander Glennon, Tracewell Cara Ann, Tymoshenko Stepan, WANG Zhihao

Принадлежит: Zymergen Inc.

The present disclosure describes the engineering of microbial cells for fermentative production of 2-oxoadipate and provides novel engineered microbial cells and cultures, as well as related 2-oxoadipate production methods. 1. An engineered microbial cell that expresses a heterologous homocitrate synthase , wherein the engineered microbial cell produces 2-oxoadipate.2. The engineered microbial cell of claim 1 , wherein the engineered microbial cell also expresses a heterologous homoaconitase.3. The engineered microbial cell of or claim 1 , wherein the engineered microbial cell also expresses a heterologous homoisocitrate dehydrogenase.4. The engineered microbial cell of any one of - claim 1 , wherein the engineered microbial cell expresses one or more additional enzyme(s) selected from an additional heterologous homocitrate synthase claim 1 , an additional heterologous homoaconitase claim 1 , or an additional heterologous homoisocitrate dehydrogenase.5. An engineered microbial cell that expresses a non-native homocitrate synthase claim 1 , wherein the engineered microbial cell produces 2-oxoadipate.6. The engineered microbial cell of claim 5 , wherein the engineered microbial cell also expresses a non-native homoaconitase.7. The engineered microbial cell of or claim 5 , wherein the engineered microbial cell also expresses a non-native homoisocitrate dehydrogenase.8. The engineered microbial cell of any one of - claim 5 , wherein the engineered microbial cell expresses one or more additional enzyme(s) selected from an additional non-native homocitrate synthase claim 5 , an additional non-native homoaconitase claim 5 , or an additional non-native homoisocitrate dehydrogenase.98. The engineered microbial cell of claim 5 , wherein the additional enzyme(s) are from a different organism than the corresponding enzyme in -.10. The engineered microbial cell of any of - claim 5 , wherein the engineered microbial cell comprises increased activity of one or more upstream 2- ...

Подробнее

Номер записи: 55

03-02-2022 дата публикации

PROGRAMMED MICROORGANISMS TO ATTENUATE A DISEASE

Номер: US20220033867A1

Автор: KUMAR Arumbuliyur Sathish, MURALI Panchapagesa Muthuswamy, Raghavan Shriram

Принадлежит:

The present disclosure discloses a recombinant microbe producing podophyllotoxin, or its derivatives, comprising genes encoding phenyl alanine ammonia-lyase (PAL), cinnamate-4-hydroxylate (C4H), 4-coumaroyl CoA-ligase (4CL), hydroxycinnamoyl-CoA quinate hydroxycinnamoyltransferase (HCT), p-coumaroyl quinate 3′-hydroxylase (C3H), caffeoyl CoA O-methyltransferase (CCoAOMT), bifunctional pineresionl-lariciresinol reductase (DIRPLR), secoisolariciresinol dehydrogenase (SDH), cytochrome P450 oxidoreductase CYP719, O-methyltransferase (OMT), cytochrome P450 oxidoreductase CYP71, and 2-oxoglutarate/Fe(II)-dependent dioxygenase (2-ODD). Also disclosed herein is a method for producing podophyllotoxin or its derivatives. Moreover, a method of treating cancer is also disclosed. 1. A recombinant microbe producing podophyllotoxin , or its derivatives , comprising genes encoding phenyl alanine ammonia-lyase (PAL) , cinnamate-4-hydroxylate (C4H) , 4-coumaroyl CoA-ligase (4CL) , hydroxycinnamoyl-CoA quinate hydroxycinnamoyltransferase (HCT) , p-coumaroyl quinate 3′-hydroxylase (C3H) , caffeoyl CoA O-methyltransferase (CCoAOMT) , bifunctional pineresionl-lariciresinol reductase (DIRPLR) , secoisolariciresinol dehydrogenase (SDH) , cytochrome P450 oxidoreductase CYP719 , O-methyltransferase (OMT) , cytochrome P450 oxidoreductase CYP71 , and 2-oxoglutarate/Fe(II)-dependent dioxygenase (2-ODD).2. The recombinant microbe as claimed in claim 1 , wherein the recombinant microbe further comprises gene encoding cytochrome P450 oxidoreductase CYP82D.3. The recombinant microbe as claimed in claim 2 , wherein the recombinant microbe further comprises gene encoding UDP glucosyl transferase.4. The recombinant microbe as claimed in claim 3 , wherein the recombinant microbe further comprises gene encoding 2-Deoxy-d-ribose-5-phosphate aldolase.5. The recombinant microbe as claimed in any one of the - claim 3 , wherein two or more genes are fused to encode fusion proteins.6. The recombinant microbe ...

Подробнее

Номер записи: 56

19-01-2017 дата публикации

METHOD FOR THE PRODUCTION OF MULTIPLE-UNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS

Номер: US20170016015A1

Автор: Abbadi Amine, Bauer Jörg, Cirpus Petra, Domergue Frederic, Heinz Ernst, Kirsch Jelena, Meyer Astrid, QIU Xiao, SPERLING Petra, Vrinten Patricia, Zank Thorsten

Принадлежит:

The present invention relates to a process for the production of polyunsaturated fatty acids in an organism by introducing, into the organism, nucleic acids which encode polypeptides with Δ5-elongase activity. Advantageously, these nucleic acids can be expressed in the organism together with further nucleic acids which encode polypeptides of the biosynthesis of the fatty acid or lipid metabolism. Especially advantageous are nucleic acids which encode Δ6-desaturases, Δ5-desaturases, Δ4-desaturases and/or Δ6-elongases. These desaturases and elongases are advantageously derived from or . The invention furthermore relates to a process for the production of oils and/or triacylglycerides with an elevated content of long-chain polyunsaturated fatty acids, and oils and/or triacylglycerides thus obtained. The invention also relates to the nucleic acids, and constructs, vectors and transgenic organisms comprising the same, as well as oils, lipids and/or fatty acids produced by the process according to the invention and to their use. 1. A process for the production of a transgenic organism having a content of at least 1% by weight of docosahexaenoic acid and/or eicosapentaenoic acid based on the total lipid content of the transgenic organism , said process comprises:a) introducing, into the organism, at least one nucleic acid encoding a polypeptide with Δ6-desaturase activity;b) introducing, into the organism, at least one nucleic acid encoding a polypeptide with Δ6-elongase activity;c) introducing, into the organism, at least one nucleic acid encoding a polypeptide with Δ5-desaturase activity;d) introducing, into the organism, at least one nucleic acid encoding a polypeptide with Δ5-elongase activity; ande) introducing, into the organism, at least one nucleic acid encoding a polypeptide with Δ4-desaturase activity,wherein the at least one nucleic acid encoding a polypeptide with Δ6-desaturase activity comprises:i) the nucleotide sequence of SEQ ID NO: 17, SEQ ID NO: 19, SEQ ...

Подробнее

Номер записи: 57

03-02-2022 дата публикации

Use of acyl coenzyme a: cholesterol acyltransferase-1 in diagnosis and treatment of liver cancer

Номер: US20220034891A1

Автор: Aihua SUN, Chaoying Li, Fuchu He, Handong WEI, Jinan ZHOU, Ying Jiang

Принадлежит: BEIJING PROTEOME RESEARCH CENTER

A use of a substance for inhibiting SOAT1 gene expression and/or protein activity. The use is selected from at least one of: (a) Preparation of kits for liver cancer diagnosis; (b) Preparation of kits for liver cancer prognosis; (c) Preparation of companion diagnostic kits for treatment of liver cancer; (d) For the preparation of drugs for the prevention and/or treatment of cancer; (e) For the preparation of drugs for the prevention and/treatment of cancer spread and metastasis; (f) For the preparation of drugs that promote the apoptosis of cancer cells; (g) For the preparation of drugs for inhibiting cancer cell formation; (h) For the preparation of drugs that inhibit the proliferation and growth of cancer cells in vitro. Experiments have shown that SOAT1 is highly expressed in liver cancer tissues and serum, and its high abundance indicates poor prognosis of liver cancer patients.

Подробнее

Номер записи: 58

21-01-2016 дата публикации

METHODS FOR REGULATING NITROGEN METABOLISM DURING THE PRODUCTION OF ETHANOL FROM CORN BY METABOLICALLY ENGINEERED YEAST STRAINS

Номер: US20160017377A1

Автор: Argyros Aaron, Barrett Trisha

Принадлежит:

The present invention provides for a mechanism to reduce glycerol production and increase nitrogen utilization and ethanol production of recombinant microorganisms. One aspect of this invention relates to strains of with reduced glycerol productivity that get a kinetic benefit from higher nitrogen concentration without sacrificing ethanol yield. A second aspect of the invention relates to metabolic modifications resulting in altered transport and/or intracellular metabolism of nitrogen sources present in com mash.

Подробнее

Номер записи: 59

21-01-2016 дата публикации

PRODUCTION OF FATTY ACIDS BY HETEROLOGOUS EXPRESSION OF GENE CLUSTERS FROM MYXOBACTERIA

Номер: US20160017388A1

Автор: Gemperlein Katja, Mueller Rolf, Rachid Shwan, Wenzel Silke

Принадлежит:

The invention relates to a process for producing one or more polyunsaturated fatty acids by means of heterologous gene expression comprising the steps of providing a production organism which comprises a heterologous gene cluster encoding a polyunsaturated fatty acid biosynthetic pathway encompassing a subsequence ER encoding an enoylreductase and a subsequence AT encoding an acyltransferase,

Подробнее

Номер записи: 60

21-01-2021 дата публикации

METHOD FOR THE PURIFICATION OF BIOLOGICAL MACROMOLECULAR COMPLEXES

Номер: US20210017224A1

Автор: CHARI Ashwin, HENNEBERG Fabian, SCHRADER Jil, STARK Holger

Принадлежит:

The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided. Said method is particularly useful in personalized medicine identifying suitable inhibitors of the 20S proteasome in individuals for treating, ameliorating or preventing a cancer, an autoimmune disease, a muscular dystrophy, emphysema or cachexia accompanying cancer or AIDS. 18-. (canceled)9. A method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual comprising: a) providing a crude sample containing the biological macromolecular complexes;', 'b) conducting a first centrifugation step for separation of cell debris at 25,000 to 35,000×g;', 'c) supplementing the supernatant obtained from the first centrifugation step with an osmolyte in an amount of from 0% to 25% (w/v) and compounds allowing thiol-alkylation of cystienes;', 'd) conducting a second centrifugation step by centrifugation at 50.000 to 150.000×g;', 'e) treating the supernatant obtained from the second centrifugation step with a water-soluble polymer for precipitation;', 'f) conducting a density gradient centrifugation using the osmolyte with a polymer-based precipitate, after resuspension thereof in a ...

Подробнее

Номер записи: 61

15-01-2015 дата публикации

HIBISCUS CANNABINUS FERULOYL-COA:MONOLIGNOL TRANSFERASE

Номер: US20150020234A1

Автор: Ralph John, Wilkerson Curtis, Withers Saunia

Принадлежит:

The invention relates to isolated nucleic acids encoding a feruloyl-CoA:monolignol transferase and feruloyl-CoA:monolignol transferase enzymes. The isolated nucleic acids and/or the enzymes enable incorporation of monolignol ferulates into the lignin of plants, where such monolignol ferulates include, for example, p-coumaryl ferulate, coniferyl ferulate, and/or sinapyl ferulate. The invention also includes methods and plants that include nucleic acids encoding a feruloyl-CoA:monolignol transferase enzyme and/or feruloyl-CoA:monolignol transferase enzymes. 1Hibiscus cannabinus. An isolated (Kenaf) feruloyl-CoA:monolignol transferase nucleic acid with at least about 95% sequence identity to nucleic acid sequence SEQ ID NO:8.2Hibiscus cannabinus. The isolated nucleic acid of claim 1 , wherein the nucleic acid encodes a (Kenaf) feruloyl-CoA:monolignol transferase polypeptide with amino acid sequence SEQ ID NO:9 or SEQ ID NO:16.3. An expression cassette comprising a feruloyl-CoA:monolignol transferase nucleic acid segment with at least about 95% sequence identity to nucleic acid sequence SEQ ID NO:8 claim 1 , and a promoter operably linked to the nucleic acid segment claim 1 , wherein the promoter is functional in a host cell.4Hibiscus cannabinus. The expression cassette of claim 3 , wherein the nucleic acid segment encodes a (Kenaf) feruloyl-CoA:monolignol transferase polypeptide with amino acid sequence SEQ ID NO:9 or SEQ ID NO:16.5. The expression cassette of claim 3 , wherein the promoter is a promoter functional or active during plant development or growth.6. The expression cassette of claim 3 , wherein the promoter is a promoter functional or active in woody tissues of a plant.7. An isolated cell comprising the isolated feruloyl-CoA:monolignol transferase nucleic acid of .8. The isolated cell of claim 7 , which is a microorganism or a plant cell.9. A plant comprising the isolated cell of .10. A plant comprising a heterologous feruloyl-CoA:monolignol transferase ...

Подробнее

Номер записи: 62

17-01-2019 дата публикации

COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES

Номер: US20190017998A1

Автор: Cathers Brian E., Chamberlain Philip, Lopez-Girona Antonia, Lu Gang

Принадлежит:

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins. 1. A degron in a CRBN-associated protein (CAP) , wherein the degron is a structural degron.2. The degron of claim 1 , wherein the structural degron comprises an α-turn.3. The degron of or claim 1 , comprising 4 amino acid residues claim 1 , with positions designated as i claim 1 , i+1 claim 1 , i+2 claim 1 , and i+3 claim 1 , respectively.4. The degron of claim 3 , further comprising an amino acid residue at position i−1.5. The degron of or claim 3 , wherein the amino acid residues at position i claim 3 , i+1 claim 3 , or i+2 form hydrogen bonds with amino acid residues on CRBN.6. The degron of or claim 3 , wherein the amino acid residues at position i claim 3 , i+1 claim 3 , and i+2 form hydrogen bonds with amino acid residues on CRBN.7. The degron of any one of - claim 3 , wherein the amino acid residue at position i+3 is Glycine (G).8. The degron of any one of - claim 3 , wherein the degron is stabilized by internal hydrogen bonds from an ASX motif and a ST motif.9. The degron of any one of - claim 3 , comprising an ASX motif that starts with Aspartic Acid (D).10. The degron of any one of - claim 3 , comprising an ASX motif that starts with Asparagine (N).11. The degron of any one of - claim 3 , comprising a ST motif that starts with Serine (S).12. The degron of any one of - claim 3 , comprising a ST motif that starts with Threonine (T).13. The degron of any one of - claim 3 , comprising an amino acid sequence of [D/N]XX[S/T]G claim 3 , wherein X can be any amino acid residue.14. The degron of claim 13 , comprising an amino acid sequence of DXXSG.15. The degron of any one of - claim 13 , comprising an amino acid sequence of CXXCG claim 13 , wherein X can be any amino acid residue.16. The degron ...

Подробнее

Номер записи: 63

21-01-2021 дата публикации

BROAD-SPECTRUM PROTEOME EDITING WITH AN ENGINEERED BACTERIAL UBIQUITIN LIGASE MIMIC

Номер: US20210017503A1

Автор: DeLisa Matthew P., Hammond Paula T., LUDWICKI Morgan B.

Принадлежит:

The present application relates to an isolated chimeric molecule comprising a degradation domain comprising an E3 ubiquitin ligase (E3) motif and a targeting domain capable of specifically directing the degradation domain to a substrate, where the targeting domain is heterologous to the degradation domain. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers. 1. An isolated chimeric molecule comprising:a degradation domain comprising an E3 ubiquitin ligase (E3) motif;a targeting domain capable of specifically directing said degradation domain to a substrate, wherein said targeting domain is heterologous to said degradation domain; anda linker coupling said degradation domain to said targeting domain.2. The chimeric molecule of claim 1 , wherein said E3 motif comprises a modified binding region which inhibits or decreases binding to said substrate compared to said E3 motif without the modified binding region.3. The chimeric molecule of claim 2 , wherein the modification is a mutation or deletion in said binding region.4. The chimeric molecule of claim 1 , wherein said E3 motif permits proteolysis of said substrate.5. The chimeric molecule of claim 1 , wherein said E3 motif possesses a cell-type specific or tissue specific ligase function.6. The chimeric molecule of claim 5 , wherein said ligase function is cell-type specific and the cell-type is selected from the group consisting of skin cells claim 5 , muscle cells claim 5 , epithelial cells claim 5 , endothelial cells claim 5 , stem cells claim 5 , umbilical vessel cells claim 5 , corneal cells claim 5 , cardiomyocytes claim 5 , aortic cells claim 5 , corneal epithelial cells claim 5 , somatic cells claim 5 , fibroblasts claim 5 , keratinocytes claim 5 , melanocytes claim 5 , adipose cells claim 5 , ...

Подробнее

Номер записи: 64

16-01-2020 дата публикации

SYNTHETIC METHYLOTROPHS AND USES THEREOF

Номер: US20200017888A1

Автор: Antoniewicz Maciek, Bennett Robert Kyle, Gonzalez Jacqueline, Papoutsaki Eleftherios T., Whitaker William Brian

Принадлежит: University of Delaware

The present invention provides a method for increasing production of a metabolite by a non-naturally occurring methylotroph, comprising growing the non-naturally occurring methylotroph in a medium comprising methanol. Expression of one or more native genes in the non-naturally occurring methylotroph is changed. Also provided are the non-naturally occurring methylotroph and preparation thereof. 1. A method for increasing production of a metabolite by a non-naturally occurring methylotroph , comprising growing the non-naturally occurring methylotroph in a medium comprising methanol , wherein expression of one or more native genes in the non-naturally occurring methylotroph is changed.2. The method of claim 1 , wherein the one or more native genes comprise 2 claim 1 ,3-bisphosphoglycerate-dependent phosphoglycerate mutase gene (gpmA) claim 1 , 2 claim 1 ,3-bisphosphoglycerate-independent phosphoglycerate mutase gene (gpmM) claim 1 , 2-dehydro-3-deoxy-D-gluconate 6-phosphate (KDPG) aldolase gene (eda) claim 1 , 6-phosphogluconate dehydrogenase gene (gnd) claim 1 , aminomethyltransferase gene (gcvT) claim 1 , bifunctional (p)ppGpp synthetase II/guanosine-3′ claim 1 ,5′-bis pyrophosphate 3′-pyrophosphohydrolase gene (spoT) claim 1 , enolase gene (eno) claim 1 , fructose-1 claim 1 ,6-bisphosphatase 1 class 2 gene (glpX) claim 1 , fructose-1 claim 1 ,6-bisphosphatase class 1 gene (fbp) claim 1 , GDP pyrophosphokinase/GTP pyrophosphokinase gene (relA) claim 1 , glucose-6-phosphate isomerase gene (pgi) claim 1 , glyceraldehyde-3-phosphate dehydrogenase gene (gapA) claim 1 , glyceraldehyde-3-phosphate dehydrogenase gene (gapC) claim 1 , glycine cleavage system H protein gene (gcvH) claim 1 , glycine decarboxylase gene (gcvP) claim 1 , HTH-type transcriptional regulator GntR gene (gntR) claim 1 , leucine-responsive regulatory protein gene (lrp) claim 1 , methylglyoxal synthase gene (mgsA) claim 1 , phosphogluconate dehydratase gene (edd) claim 1 , phosphoglycerate dehydrogenase ...

Подробнее

Номер записи: 65

16-01-2020 дата публикации

Production of Cannabigerolic Acid in Yeast

Номер: US20200017889A1

Автор: FARNIA ANTHONY N., Poulos Jason L.

Принадлежит:

Exemplary embodiments provided herein include genetically engineering microorganisms, such as yeast or bacteria, to produce cannabinoids by inserting genes that produce the appropriate enzymes for the metabolic production of a desired compound. 1. A method for making cannabigerolic acid , the method comprising:{'i': 'S. cerevisiae', 'transforming a with a first nucleotide sequence of SEQ ID NO 1 expressing an acyl-activating enzyme;'}{'i': 'S. cerevisiae', 'transforming the with a second nucleotide sequence of SEQ ID NO 22 expressing a mutant prenyltransferase;'}{'i': 'S. cerevisiae', 'transforming the with a third nucleotide sequence of SEQ ID NO 10 expressing olivetolic synthase;'}{'i': 'S. cerevisiae', 'transforming the with a fourth nucleotide sequence of SEQ ID NO 5 expressing olivetolic acid cyclase; and'}{'i': 'S. cerevisiae', 'transforming the with a fifth nucleotide sequence of SEQ ID NO A expressing aromatic prenyltransferase.'}2. The method for making cannabigerolic acid of claim 1 , wherein SEQ ID NO A is any of: SEQ ID NO 30 claim 1 , SEQ ID NO 31 claim 1 , SEQ ID NO 32 claim 1 , SEQ ID NO 36 claim 1 , SEQ ID NO 37 claim 1 , SEQ ID NO 38 claim 1 , SEQ ID NO 42 claim 1 , SEQ ID NO 43 claim 1 , SEQ ID NO 44 claim 1 , SEQ ID NO 48 claim 1 , SEQ ID NO 49 claim 1 , SEQ ID NO 50 claim 1 , SEQ ID NO 54 claim 1 , SEQ ID NO 55 claim 1 , and SEQ ID NO 56.3. A method for making cannabigerolic acid claim 1 , the method comprising:{'i': 'S. cerevisiae', 'transforming a with a first nucleotide sequence of SEQ ID NO 1 expressing an acyl-activating enzyme;'}{'i': 'S. cerevisiae', 'transforming the with a second nucleotide sequence of SEQ ID NO 22 expressing a mutant prenyltransferase;'}{'i': 'S. cerevisiae', 'transforming the with a third nucleotide sequence of SEQ ID NO B expressing olivetolic synthase;'}{'i': 'S. cerevisiae', 'transforming the with a fourth nucleotide sequence of SEQ ID NO 5 expressing olivetolic acid cyclase; and'}{'i': 'S. cerevisiae', ' ...

Подробнее

Номер записи: 66

16-01-2020 дата публикации

MUTANT YEAST STRAIN CAPABLE OF PRODUCING MEDIUM CHAIN FATTY ACIDS

Номер: US20200017892A1

Автор: ANDRE Isabelle, Barbe Sophie, BORDES Florence, Croux Christian, Daboussi Fayza, Gueroult Marc, Marty Alain, Percheron Benjamin, Rigouin Coraline

Принадлежит:

Embodiments of the present disclosure relate to mutant yeast strains, in particular mutant strains, capable of producing medium chain fatty acids compared to the parent oleaginous yeast strain from which said mutant oleaginous yeast strain derives. Embodiments of the present disclosure also relate to means and methods for obtaining these mutant yeast strains. 1. A method for increasing the ratio of fatty acids having a hydroxycarbon chain length consisting of 16 carbons (C16 fatty acids) to fatty acids having a hydroxycarbon chain consisting of 18 carbons (C18 fatty acids) and/or for increasing the amount of medium chain length fatty acids (C8-C15 fatty acids) , produced by a yeast strain , compared to the parent yeast strain from which said yeast strain derives , comprising expressing in said yeast strain a mutated fatty acid synthase subunit alpha (αFAS) , wherein the amino acid residue of said αFAS corresponding to the amino acid residue at position 1220 in SEQ ID NO: 1 is substituted with a larger steric hindrance amino acid residue.2. The method according to claim 1 , wherein:when the amino acid residue corresponding to the amino acid residue at position 1220 in SEQ ID NO: 1 of the non-mutated αFAS is isoleucine (I) then it is substituted with an amino acid residue selected from the group consisting of phenylalanine (F), histidine (H), methionine (M), tryptophan (W) and tyrosine (Y),when the amino acid residue corresponding to the amino acid residue at position 1220 in SEQ ID NO: 1 of the non-mutated αFAS is valine (V) then it is substituted with an amino acid residue selected from the group consisting of isoleucine (I) phenylalanine (F), histidine (H), methionine (M), tryptophan (W) and tyrosine (Y), andwhen the amino acid residue corresponding to the amino acid residue at position 1220 in SEQ ID NO: 1 of the non-mutated αFAS is methionine (M) then it is substituted with an amino acid residue selected from the group consisting of phenylalanine (F), histidine ( ...

Подробнее

Номер записи: 67

10-02-2022 дата публикации

BREAST AND OVARIAN CANCER VACCINES

Номер: US20220040275A1

Автор: CECIL Denise, DISIS Mary L., SLOTA Meredith

Принадлежит: University of Washington through its Center for Commercialization

The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof. 1223-. (canceled)224. A composition comprising a plurality of epitopes , wherein the epitopes comprise an amino acid sequence having at least 95% sequence identity to the IGFBP-2 amino acid sequence of SEQ ID NO: 54 , an amino acid sequence having at least 95% sequence identity to the Survivin amino acid sequence of SEQ ID NO: 85 , an amino acid sequence having at least 95% sequence identity to the HIF1A amino acid sequence of SEQ ID NO: 87 , and an amino acid sequence having at least 95% sequence identity to the IGF1R amino acid sequence of SEQ ID NO: 73.225. A composition comprising a fusion protein having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 89 , wherein the fusion protein comprises a plurality of epitopes , and wherein the plurality of epitopes comprises the amino acid sequences of SEQ ID NO: 54 , SEQ ID NO: 73 , SEQ ID NO: 85 and SEQ ID NO: 87.226. The composition of claim 225 , wherein the fusion protein has at least 99% sequence identity to SEQ ID NO: 89.227. The composition of claim 225 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 89.228. The composition of claim 225 , wherein the fusion protein consists of the amino acid sequence of SEQ ID NO: 89.229. The composition of claim 225 , further comprising a pharmaceutically acceptable carrier claim 225 , an adjuvant claim 225 , a chemotherapeutic agent claim 225 , or a combination thereof.230. The composition of claim 229 , wherein the adjuvant is GM-CSF.231. The composition of claim 229 , wherein the chemotherapeutic agent is cisplatin.232. The composition of claim 225 , wherein the plurality of ...

Подробнее

Номер записи: 68

28-01-2016 дата публикации

Atp driven direct photosynthetic production of fuels and chemicals

Номер: US20160024532A1

Автор: Ethan I. Lan, James C. Liao

Принадлежит: UNIVERSITY OF CALIFORNIA

Provided herein are metabolically-modified microorganisms useful for producing biofuels. More specifically, provided herein are methods of producing high alcohols including isobutanol, 1-butanol, 1-propanol, 2-methyl-l-butanol, 3-methyl-1-butanol and 2-phenylethanol from a suitable substrate.

Подробнее

Номер записи: 69

28-01-2016 дата публикации

Compositions and Methods of Producing Methionine

Номер: US20160024541A1

Автор: Brian Brazeau, Fernando A. Sanchez-Riera, Holly J. Jessen, Hyewon Um, Jin-sook Chang, Kwang Myung Cho, Mervyn DeSouza, So-Young Kim, Wei Niu, Yong-Uk Shin, Young Wook CHO

Принадлежит: CJ CHEILJEDANG CORP

Described herein are microorganisms that produce methionine and related products from endogenous genes in a transsulfuration pathway, as well as from exogenous genes providing a direct sulfhydrylation pathway. Novel genes that are useful for methionine and SAMe production are disclosed.

Подробнее

Номер записи: 70

22-01-2015 дата публикации

MICROORGANISMS FOR THE PRODUCTION OF MELATONIN

Номер: US20150024440A1

Автор: Forster Jochen, Knight Eric Michael, Luo Hao, Zhu Jiangfeng

Принадлежит:

Recombinant microbial cells and methods for producing melatonin and related compounds using such cells are described. More specifically, the recombinant microbial cell may comprise exogenous genes encoding one or more of an L-tryptophan hydroxylase, a 5-hydroxy-L-tryptophan decarboxylyase, a serotonin acetyltransferase, an acetylserotonin O-methyltransferase; an L-tryptophan decarboxy-lyase, and a tryptamine-5-hydroxylase, and means for providing tetrahydrobiopterin (THB). Related sequences and vectors for use in preparing such recombinant microbial cells are also described. 1. A recombinant microbial cell comprising exogenous nucleic acid sequences encoding an L-tryptophan hydroxylase (EC 1.14.16.4) , a 5-hydroxy-L-tryptophan decarboxylyase (EC 4.1.1.28) , a serotonin acetyltransferase (EC 2.3.1.87) , an acetylserotonin O-methyltransferase (EC 2.1.1.4) , and enzymes of at least one pathway for producing tetrahydrobiopterin (THB).2. A recombinant microbial cell comprising exogenous nucleic acid sequences encoding an L-tryptophan hydroxylase (EC 1.14.16.4) , a 5-hydroxy-L-tryptophan decarboxylyase (EC 4.1.1.28) , and enzymes of at least one pathway for producing tetrahydrobiopterin (THB) , and , optionally , a serotonin acetyltransferase (EC 2.3.1.87).3. The recombinant microbial cell of any one of the preceding claims , comprising exogenous nucleic acid sequences encoding enzymes of a first and/or a second pathway for producing THB , the first pathway producing THB from guanosin triphosphate (GTP) , and the second pathway regenerating THB from 4a-hydroxytetrahydrobiopterin.4. The recombinant microbial cell of claim 3 , wherein the enzymes of the first pathway comprise(a) optionally, a GTP cyclohydrolase I (EC 3.5.4.16);(b) a 6-pyruvoyl-tetrahydropterin synthase (EC 4.2.3.12); and(c) a sepiapterin reductase (EC 1.1.1.153).5. The recombinant microbial cell of any one of and claim 3 , wherein the enzymes of the second pathway comprise(a) a 4a-hydroxytetrahydrobiopterin ...

Подробнее

Номер записи: 71

22-01-2015 дата публикации

Modified diacylglycerol acyltransferase proteins and methods of use thereof

Номер: US20150024442A1

Автор: James Roberts, Jason W. Hickman, Kimberly Marie Kotovic, Michael Carleton, Tracey Jurista

Принадлежит: Matrix Genetics LLC

Provided are fusion proteins of diacylglycerol acyltransferase (DGAT) polypeptides fused to at least one heterologous intracellular localization domain, such as a bacterial membrane-targeting domain, modified photosynthetic microorganism that comprise such fusion proteins, and related methods for improving the production of lipids by photosynthetic microorganisms, including lipids such as triglycerides, fatty acids, and wax esters.

Подробнее

Номер записи: 72

22-01-2015 дата публикации

PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION

Номер: US20150024485A1

Автор: DUPRAZ PHILIPPE, KOBR MICHEL

Принадлежит:

This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR). 1. An isolated nucleic acid encoding a Puro-DHFR polypeptide , wherein said Puro-DHFR polypeptide comprises SEQ ID NO: 2 and has: (i) puromycin N-acetyl transferase activity; and (ii) dihydrofolate reductase activity.2. A vector comprising the isolated nucleic acid according to .3. The vector according to claim 2 , wherein said vector is an expression vector further comprising a nucleic acid encoding a protein of interest.4. The vector according to claim 3 , wherein said vector comprises at least two promoters claim 3 , the first promoter driving the expression of the Puro-DHFR polypeptide and the second promoter driving the expression of the protein of interest.5. The vector according to claim 4 , wherein the nucleic acid encoding the Puro-DHFR polypeptide is driven by the same promoter as the nucleic acid encoding said protein of interest claim 4 , and wherein said vector comprises either an internal ribosome entry site (IRES) or a 2A sequence located between said nucleic acids.6. An isolated cell comprising a nucleic acid according to .7. The isolated cell according to claim 6 , wherein said cell is selected from the group consisting of a human cell claim 6 , a CHO cell claim 6 , a murine cell and a hybridoma. This application is a divisional of U.S. application Ser. No. 13/742,495, filed Jan. 16, 2013, which is a divisional of U.S. application Ser. No. 12/601,553, filed Nov. 24, 2009, now U.S. Pat. No. 8,357, ...

Подробнее

Номер записи: 73

26-01-2017 дата публикации

METHOD FOR PRODUCING METHACRYLIC ACID ESTER AND NOVEL METHACRYLIC ACID ESTER SYNTHETASE

Номер: US20170022525A1

Автор: Asano Yasuhisa, MIZUNASHI Wataru, SATO Eiji, Yu Fujio

Принадлежит: MITSUBISHI RAYON CO., LTD.

Provided is a method for producing a methacrylic acid ester using a biocatalyst, said method comprising a step of reacting an alcohol or a phenol with methacrylyl-CoA in the presence of an alcohol acyltransferase originated from a plant selected from the group consisting of a plant belonging to the genus a plant belonging to the genus a plant belonging to the genus a plant belonging to the genus a plant belonging to the genus and a plant belonging to the genus to thereby synthesize the methacrylic acid ester. 1. A method for producing a methacrylic acid ester , comprising:{'i': Lamiales, Vitales, Sapindales, Malvales, Magnoliales', 'Asterales., 'synthesizing a methacrylic acid ester by reacting alcohol or phenol with methacrylyl-CoA in the presence of an alcohol acyltransferase derived from a plant selected from the group consisting of plants that belong to and'}2. A method for producing a methacrylic acid ester , comprising:synthesizing a methacrylic acid ester by reacting alcohol or phenol with methacrylyl-CoA in the presence of an alcohol acyltransferase derived from a plant selected from the group consisting of plants that belong to Oleaceae, Vitaceae, Rutaceae, Malvaceae, Magnoliaceae and Asteraceae.3. An alcohol acyltransferase or its composition , having the following (1)˜(5) physicochemical properties:(1) producing a methacrylic acid ester by reacting with methacrylyl-CoA in the presence of alcohol or phenol;(2) having a higher activity on methacrylyl-CoA than on acetyl-CoA;(3) having a higher activity on isobutyryl-CoA than on acetyl-CoA;(4) having a Km value of 0.05 mM or lower for methacrylyl-CoA; and(5) having an optimum pH of 8˜9 when using methacrylyl-CoA and n-butanol as the substrate.4. A method for producing an organic acid ester by using the acyltransferase or its composition according to .5. A method for producing a methacrylic acid ester claim 3 , comprising:{'i': Osmanthus, Vitis, Citrus, Durio, Magnolia', 'Chamaemelum., 'synthesizing a ...

Подробнее

Номер записи: 74

25-01-2018 дата публикации

COMPOSITIONS AND METHODS FOR EPIGENOME EDITING

Номер: US20180023064A1

Автор: Gersbach Charles A., Hilton Isaac

Принадлежит:

Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems. 1. A fusion protein comprising two heterologous polypeptide domains , wherein the first polypeptide domain comprises a Clustered Regularly Interspaced Short Palindromic Repeats associated (Cas) protein and the second polypeptide domain comprises a peptide having histone acetyltransferase activity.2. The fusion protein of claim 1 , wherein the fusion protein activates transcription of a target gene.3. The fusion protein of or claim 1 , wherein the Cas protein comprises Cas9.4. The fusion protein of claim 3 , wherein the Cas9 comprises at least one amino acid mutation which knocks out nuclease activity of Cas9.5. The fusion protein of claim 4 , wherein the Cas protein comprises SEQ ID NO: 1 or SEQ ID NO: 10.6. The fusion protein of any one of - claim 4 , wherein the second polypeptide domain comprises a histone acetyltransferase effector domain.7. The fusion protein of claim 6 , wherein the histone acetyltransferase effector domain is a p300 histone acetyltransferase effector domain.8. The fusion protein of any one of - claim 6 , wherein the second polypeptide domain comprises SEQ ID NO: 2 or SEQ ID NO: 3.9. The fusion protein of any one of - claim 6 , wherein the first polypeptide domain comprises SEQ ID NO: 1 or SEQ ID NO: 10 and the second polypeptide domain comprises SEQ ID NO: 2 or SEQ ID NO. 3.10. The fusion protein of any one of - claim 6 , wherein the first polypeptide domain comprises SEQ ID NO: 1 and the second polypeptide domain comprises SEQ ID NO. 3 claim 6 , or the first polypeptide domain comprises SEQ ID NO: 10 and the second polypeptide domain comprises SEQ ID NO. 3.11. The fusion protein of any one of - claim 6 , further comprising a linker connecting the first polypeptide domain to the second polypeptide domain.12. The fusion protein of any one of - ...

Подробнее

Номер записи: 75

25-01-2018 дата публикации

Methods for plant transformation using spectinomycin selection

Номер: US20180023090A1

Автор: Brian J. Martinell, David A. Somers, Edward Williams, Michael W. Petersen, Xudong Ye, Yuechun Wan

Принадлежит: MONSANTO TECHNOLOGY LLC

The present invention relates to methods and compositions for transforming soybean, corn, cotton, or canola explants using spectinomycin as a selective agent for transformation of the explants. The method may further comprise treatment of the explants with cytokinin during the transformation and regeneration process.

Подробнее

Номер записи: 76

25-01-2018 дата публикации

MICROORGANISMS AND METHODS FOR THE CO-PRODUCTION OF ETHYLENE GLYCOL AND THREE CARBON COMPOUNDS

Номер: US20180023101A1

Автор: KOCH Daniel Johannes, Lopes Mateus Schreiner, Parizzi Lucas Pedersen, Zeidler Ane Fernanda Beraldi

Принадлежит:

The present application relates to recombinant microorganisms useful in the biosynthesis of monoethylene glycol (MEG) and one or more three-carbon compounds such as acetone, isopropanol or propene. The MEG and one or more three-carbon compounds described herein are useful as starting material for production of other compounds or as end products for industrial and household use. The application further relates to recombinant microorganisms co-expressing a C2 branch pathway and a C3 branch pathway for the production of MEG and one or more three-carbon compounds. Also provided are methods of producing MEG and one or more three-carbon compounds using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or optionally the products MEG and one or more three-carbon compounds. 2. The recombinant microorganism of claim 1 , wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding a secondary alcohol dehydrogenase that catalyzes the conversion of acetone to isopropanol.3. The recombinant microorganism of claim 1 , wherein the recombinant microorganism further comprises: at least one endogenous or exogenous nucleic acid molecule encoding a secondary alcohol dehydrogenase that catalyzes the conversion of acetone to isopropanol; and at least one endogenous or exogenous nucleic acid molecule encoding a dehydratase that catalyzes the conversion of isopropanol to propene.4. The recombinant microorganism of claim 1 , wherein the recombinant microorganism further comprises one or more modifications selected from the group consisting of:(a) a deletion, insertion, or loss of function mutation in a gene encoding a D-xylose isomerase that catalyzes the conversion of D-xylose to D-xylulose;(b) a deletion, insertion, or loss of function mutation in a gene encoding a glycolaldehyde dehydrogenase that catalyzes the conversion of glycolaldehyde to glycolic acid; and(c) a deletion, ...

Подробнее

Номер записи: 77

25-01-2018 дата публикации

MATERIALS AND METHODS FOR DIRECTING CARBON FLUX AND INCREASED PRODUCTION OF CARBON BASED CHEMICALS

Номер: US20180023104A1

Автор: Cartman Stephen, Combe Jonathan, Foster Alexander B., KENNEDY Jonathan

Принадлежит:

This disclosure relates to genome-scale attenuation or knockout strategies for directing carbon flux to certain carbon based building blocks within the 7-aminoheptanoic acid (7-AHA) and 6-aminohexanoic acid (6-AHA) biosynthesis pathways, for example, to achieve reduced flux to unwanted side products while achieving increased production of desired intermediates and end products. This disclosure also relates to non-naturally occurring mutant bacterial strains comprising one or more gene disruptions in aldehyde reductase and/or aldehyde dehydrogenase genes that are generated to direct carbon flux to certain carbon based building blocks. This disclosure further relates to a method for enhancing production of carbon based building blocks by generating non-naturally occurring mutant bacterial strains, culturing said mutant bacterial strains in the presence of suitable substrates or under desired growth conditions, and substantially purifying the desired end product. 1. A method for enhancing biosynthesis of 7-aminoheptanoic acid or 6-aminohexanoic acid comprising:a) generating a recombinant host comprising one or more gene disruptions in aldehyde reductase and/or aldehyde dehydrogenase genes, wherein said gene disruptions reduce aldehyde reductase and/or aldehyde dehydrogenase activity of polypeptides encoded by said genes, and wherein said recombinant host produces an increased level of 7-aminoheptanoic acid or 6-aminohexanoic acid converted from pimelic acid or pimelic acid derivatives or adipic acid or adipic acid derivatives as compared to a wild-type recombinant host;b) culturing said recombinant host in the presence of a suitable substrate or metabolic intermediate and under conditions suitable for the conversion of pimelic acid or pimelic acid derivatives to 7-aminoheptanoic acid or adipic acid or adipic acid derivatives to 6-aminohexanoic acid; andc) obtaining the 7-aminoheptanoic acid or 6-aminohexanoic acid.2. The method of claim 1 , wherein said pimelic acid ...

Подробнее

Номер записи: 78

23-01-2020 дата публикации

HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS

Номер: US20200022942A1

Автор: ALLEN Lisha, Hu Sean

Принадлежит:

The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions. 120-. (canceled)22. The method of claim 21 , wherein the antibody drug conjugate is N-glycosylated in the Fc region.23. The method of claim 21 , wherein the antibody is a human antibody.24. The method of claim 21 , wherein the antibody is a humanized antibody.25. The method of claim 21 , wherein both heavy chains of the antibody are conjugated to the conjugation moiety.26. The method of claim 21 , wherein the antibody is an anti-Her2 antibody.27. The method of claim 26 , wherein the antibody is trastuzumab.28. The method of claim 26 , wherein the anti-Her2 antibody is N-glycosylated in the Fc region.29. The method of claim 26 , wherein the anti-Her2 antibody is N-glycosylated at position 297 claim 26 , wherein the anti-Her2 antibody is conjugated to a conjugation moiety via an endogenous acceptor glutamine residue at position 295.30. The method of claim 21 , wherein the cancer is a Her2+ cancer.31. The method of claim 21 , wherein the cancer is selected from the group consisting of pancreatic cancer claim 21 , ovarian cancer claim 21 , colon cancer claim 21 , breast cancer claim 21 , prostate cancer and lung cancer.32. The method of claim 29 , wherein the cancer is a Her2+ cancer.33. The method of claim 21 , wherein the antibody drug conjugate is in a pharmaceutical composition claim 21 , wherein the pharmaceutical ...

Подробнее

Номер записи: 79

10-02-2022 дата публикации

Methods for preparing n-acetyl-l-methionine

Номер: US20220042000A1

Автор: Hye Min Park, Jinseung Park, Jinwoo JEON, Jun Ok Moon, So Yeon Hong, Su Jin Choi, Sung Gun Lee

Принадлежит: CJ CHEILJEDANG CORP

The present disclosure relates to a polypeptide having an acyltransferase activity or a microorganism including the same; a composition for preparing N-acetyl-L-methionine, the composition including the polypeptide or microorganism; and a method of preparing N-acetyl-L-methionine using the polypeptide or microorganism. Further, the present disclosure relates to a polynucleotide encoding the polypeptide and an expression vector including the polynucleotide. Since the microorganism including a novel acyltransferase according to the present disclosure has enhanced acyltransferase activity, this microorganism can be efficiently used for producing N-acetyl-L-methionine by acetylating L-methionine.

Подробнее

Номер записи: 80

10-02-2022 дата публикации

Compositions and methods for converting styrene to biodegradable alternatives

Номер: US20220042025A1

Автор: Aarati Pokharel, Alec Brewer, Annabel Wright, Keith Kozminski, Kobe Rogers, Mark Kester, Simonne Guenette

Принадлежит: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Provided are nucleic acids and vectors that collectively encode various gene products related to converting styrene to polyhydroxybutyrate (PHB). In some embodiments, the nucleic acids and vectors collectively encode a styrene monooxygenase polypeptide, a flavin reductase polypeptide, a styrene-oxide isomerase polypeptide, and a phenylacetaldehyde dehydrogenase polypeptide, an acetyl-CoA C-acetyltransferase polypeptide, a 3-ketoacyl-ACP reductase polypeptide, a class I poly(R)-hydroxyalkanoic acid synthase polypeptide, and optionally an influx porin polypeptide. Also provided are systems and methods for producing PHB from styrene, methods and systems for remediating polystyrene waste. In some embodiments, the systems are in vivo systems.

Подробнее

Номер записи: 81

10-02-2022 дата публикации

PRODUCTION OF DHA AND OTHER LC PUFAS IN PLANTS

Номер: US20220042028A1

Автор: Bevan Scott, Gachotte Daniel, Kuner Jerry, Merlo Ann Owens, Metz James, Pareddy Dayakar Reddy, Walsh Terence A.

Принадлежит:

The invention provides recombinant host organisms genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins that allow for and/or improve the production of PUFAs in the host organism. The present invention also relates to methods of making and using such organisms as well as products obtained from such organisms. 1. A method of genetically modifying a soybean plant , descendant , cell , tissue , seed or part thereof , comprising modifying a soybean plant to include:(i) a nucleic acid molecule comprising a soybean codon-optimized coding sequence encoding an algal polyunsaturated fatty acid (PUFA) synthase that produces at least one PUFA; and(ii) a nucleic acid molecule comprising a soybean codon-optimized coding sequence encoding algal phosphopantetheinyl transferase (PPTase).2SchizochytriumThraustochytrium microalgae.. The method of claim 1 , wherein the PUFA synthase and the PPTase enzymes are from or3. The method of claim 1 , wherein the PUFA synthase comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:6 claim 1 , SEQ ID NO:7 claim 1 , or SEQ ID NO:8.4. The method of claim 1 , wherein the PUFA synthase comprises the amino acid sequence of SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:6 claim 1 , SEQ ID NO:7 claim 1 , or SEQ ID NO:8.5. The method of claim 1 , wherein the PUFA synthase comprises the amino acid sequences of SEQ ID NOs:1-3 or SEQ ID NOs:6-8.6. The method of claim 1 , wherein the PPTase comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:5 or SEQ ID NO: 10.7. The method of claim 1 , wherein the PPTase comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO: 10.8. The method of claim 3 , wherein the PPTase comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:5 or SEQ ID NO: 10.9. The method of claim ...

Подробнее

Номер записи: 82

23-01-2020 дата публикации

METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES

Номер: US20200023083A1

Автор: Chilkoti Ashutosh

Принадлежит:

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. 114-. (canceled)15. A pharmaceutical formulation comprising: a therapeutically effective amount of a chemotherapeutic agent conjugated to an elastin-like peptide (ELP) , wherein the formulation is an aqueous preparation for systemic administration , and wherein the elastin-like peptide (ELP) comprises an amino acid sequence of the formula (VPGXG) , where X is an independently selected amino acid and m is 100 or greater.16. The formulation of claim 15 , wherein the chemotherapeutic agent is enhanced for its therapeutically effective dose and/or half-life in circulation.17. The formulation of claim 15 , wherein the chemotherapeutic agent is selected from the group consisting of methotrexate claim 15 , daunomycin claim 15 , mitomycin claim 15 , cisplatin claim 15 , vincristine claim 15 , epirubicin claim 15 , fluorouracil claim 15 , verapamil claim 15 , cyclophosphamide claim 15 , cytosine arabinoside claim 15 , aminopterin claim 15 , bleomycin claim 15 , mitomycin C claim 15 , democolcine claim 15 , etoposide claim 15 , mithramycin claim 15 , chlorambucil claim 15 , melphalan claim 15 , daunorubicin claim 15 , doxorubicin claim 15 , tamoxifen claim 15 , paclitaxel claim 15 , vincristine claim 15 , vinblastine claim 15 , camptothecin claim 15 , actinomycin D claim 15 , and cytarabine.18. The formulation of claim 15 , wherein the elastin-like peptide (ELP) comprises at least one repeating block of an amino acid sequence selected from SEQ ID NOS: 1-12.19. The formulation of claim 15 , wherein the elastin-like peptide elastin-like peptide (ELP) comprises repeating blocks of VPGVG ( ...

Подробнее

Номер записи: 83

24-01-2019 дата публикации

Microorganisms of the genus corynebacterium having l-isoleucine producing ability and methods for producing l-isoleucine using the same

Номер: US20190024060A1

Автор: Jae Woo Jang, Ju Jeong Kim, Min Se KIM, Su Yon KWON

Принадлежит: CJ CHEILJEDANG CORP

The present application relates to a microorganism of the genus Corynebacterium having L-isoleucine producing ability which comprises a protein having an activity of citramalate synthase, and a method for producing L-isoleucine using the same.

Подробнее

Номер записи: 84

24-01-2019 дата публикации

A METHOD FOR PRODUCING METAL NANOPARTICLES AND METAL SULFIDE NANOPARTICLES USING A RECOMBINANT MICROORGANISM

Номер: US20190024124A1

Автор: Choi Yoojin, LEE Sang Yup

Принадлежит:

The present invention relates to a method of producing metal nanoparticles and metal sulfide nanoparticles using a recombinant microorganism co-expressing metallothionein and phytochelatin synthase, which are heavy metal-adsorbing proteins, and to the use of metal nanoparticles and metal sulfide nanoparticles synthesized by the method. The present invention provides a method for synthesizing metal nanoparticles which have been difficult to synthesize by conventional biological methods. The present invention makes it possible to synthesize metal nanoparticles in an environmentally friendly and cost-effective manner, and also makes it possible to synthesize metal sulfide nanoparticles. In addition, even metal nanoparticles which could have been produced by conventional chemical or biological methods are produced in a significantly increased yield by use of the method of the present invention. 1. A method for producing a single-element metal nanoparticle , comprising the steps of:(a) culturing a recombinant microorganism into which a metallothionein-encoding gene and a phytochelatin synthase-encoding gene are introduced;(b) adding to a medium of step (a) a metal ion selected from the group consisting of zinc (Zn), selenium (Se), tellurium (Te), cesium (Cs), copper (Cu), lead (Pb), nickel (Ni), manganese (Mn), mercury (Hg), cobalt (Co), chromium (Cr), cadmium (Cd), strontium (Sr), iron (Fe), gold (Au), silver (Ag), praseodymium (Pr), gadolinium (Gd), barium (Ba), zirconium (Zr), molybdenum (Mo), indium (In), tin (Sn), lanthanum (La), cerium (Ce), neodymium (Nd), samarium (Sm), yttrium (Y), aluminum (Al), and europium (Eu), followed by additional culturing, thereby producing a single-element metal nanoparticle; and(c) recovering the produced single-element metal nanoparticle.2. The method of claim 1 , wherein the microorganism is selected from the group consisting of bacteria claim 1 , yeasts claim 1 , algae claim 1 , archaea claim 1 , and fungi.3. The method of claim 1 ...

Подробнее

Номер записи: 85

24-01-2019 дата публикации

DESIGNER RIBOSOMES AND METHODS OF USE THEREOF FOR INCORPORATING NON-STANDARD AMINO ACIDS INTO POLYPEPTIDES

Номер: US20190024128A1

Автор: Czekster Clarissa Melo, Robertson Wesley E., Shrader Alanna Schepartz

Принадлежит:

Engineered 23S rRNAs and methods of use thereof for translation of proteins incorporating non-standard amino acids are provided. Typically, the 23S rRNA includes one or more mutations at positions 2496-2507 relative to wildtype 23S rRNA, wherein a ribosome composed of the 23S rRNA can catalyze the covalent transfer of a non-standard amino acid from an aminoacyl-RNA onto a nascent peptide chain. For example, the 23S rRNA can include the sequence UGACUU at positions 2502-2507 relative to wildtype 23S rRNA, and optionally the sequence AGCGUGA from positions 2057-2063 relative to wildtype 23S rRNA. The 23S rRNA can include additional or alternative deletions, substitutions, insertions, or combination thereof. The compositions and methods can be used to make polypeptides and sequence defined polymers. 1E. coli. A 23S rRNA comprising one or more mutations at positions 2496-2507 relative to wildtype 23S rRNA (SEQ ID NO:1) and the corresponding region of 23S mutant 040329 (SEQ ID NO:3) , wherein a ribosome comprising the 23S rRNA can catalyze the covalent transfer of a non-standard amino acid from an aminoacyl-RNA onto a nascent peptide chain.2E. coli. The 23S rRNA of comprising the sequence UGACUU at positions 2502-2507 relative to wildtype 23S rRNA.3E. coli. The 23S rRNA of comprising the sequence AGCGUGA from positions 2057-2063 relative to wildtype 23S rRNA.4. The 23S rRNA of claim 1 , comprising a truncated 5′ end claim 1 , a truncated 3′ end claim 1 , or a combination thereof relative to wildtype.5E. coli. The 23S rRNA of claim 1 , comprising one or more additional insertions claim 1 , deletions or substitutions relative to wildtype 23S rRNA.6. The 23S rRNA claim 1 , wherein the non-standard amino acid is a β3-amino acid.7E. coliE. coli. A 23S rRNA comprising a peptidyl transferase center claim 1 , wherein the peptidyl transferase center is a variant of wildtype 23S rRNA (SEQ ID NO:1) comprising the sequence UGACUU at positions 2502-2507 and the sequence AGCGUGA from ...

Подробнее

Номер записи: 86

28-01-2021 дата публикации

Novel Host Cells and Methods for Producing Isopentenol from Mevalonate

Номер: US20210023947A1

Автор: Kang Aram, Lee Taek Soon

Принадлежит:

The present invention provides for a genetically modified host cell capable of producing isopentenol and/or 3-methyl-3-butenol, comprising (a) an increased expression of phosphomevalonate decarboxylase (PMD) (b) an increased expression of a phosphatase capable of converting isopentenol into 3-methyl-3-butenol, (c) optionally the genetically modified host cell does not express, or has a decreased expression of one or more of NudB, phosphomevalonate kinase (PMK), and/or PMD, and (d) optionally one or more further enzymes capable of converting isopentenol and/or 3-methyl-3-butenol into a third compound, such as isoprene. 1. A polypeptide having a phosphomevalonate decarboxylase (PMD) enzymatic activity , and encoding an amino acid sequence comprising (a) at least 70% identity with SEQ ID NO:1 , and (b) a histidine at position 74 , a phenylalanine at position 145 , a histidine at position 74 , or a phenylalanine at position 145 , corresponding to the numbering of SEQ ID NO:1.2. The polypeptide of claim 1 , wherein the amino acid sequence comprises (i) a histidine at position 74 claim 1 , (ii) a phenylalanine at position 145 claim 1 , or (iii) a histidine at position 74 and a phenylalanine at position 145.3. The polypeptide of claim 1 , wherein the amino acid sequence comprises the following amino acid residues: E at position 71 claim 1 , S at position 108 claim 1 , N at position 110 claim 1 , A at position 119 claim 1 , S at position 120 claim 1 , S at position 121 claim 1 , A at position 122 claim 1 , S at position 155 claim 1 , R at position 158 claim 1 , S at position 208 claim 1 , and D at position 302 corresponding to SEQ ID NO:1.4. The polypeptide of claim 1 , wherein the amino acid sequence comprises at least 80% identity with SEQ ID NO:1.5. The polypeptide of claim 4 , wherein the amino acid sequence comprises at least 90% identity with SEQ ID NO:1.6. The polypeptide of claim 5 , wherein the amino acid sequence comprises at least 95% identity with SEQ ID NO:1.7. ...

Подробнее

Номер записи: 87

23-01-2020 дата публикации

PROCESS OF OMEGA-HYDROXYL FATTY ACID PRODUCTION

Номер: US20200024624A1

Автор: Cao Dong, Haas Thomas, Li Li, Pötter Markus, TAO Guoqing

Принадлежит: EVONIK DEGUSSA GmbH

Provided is a method of producing at least one omega-hydroxyl fatty acid, the method comprising: (a) contacting at least one alkane with at least one recombinant yeast cell in an aqueous medium, wherein the yeast cell is capable of oxidising the alkane to the corresponding omega-hydroxyl fatty acid and the yeast cell comprises a reduced fatty acid degradation capacity. 1: A method of producing at least one omega-hydroxyl fatty acid , the method comprising:contacting at least one alkane with at least one yeast cell in an aqueous medium,wherein the at least one yeast cell is capable of oxidizing the at least one alkane to a corresponding omega-hydroxyl fatty acid and the at least one yeast cell comprises a reduced fatty acid degradation capacity;the reduced fatty acid degradation capacity is a result of:(i) a decrease in expression relative to a wild type cell of at least one enzyme involved in a beta-oxidation pathway; and/or(ii) at least one loss-of-function mutation in at least one enzyme involved in the beta-oxidation pathway; andthe aqueous medium comprises acetate as a co-substrate.2: The method according to claim 1 , wherein an acetate concentration is at least 20 mmol/L.3: The method according to claim 1 , wherein an acetate concentration is maintained between 80-800 mmol/L.4: The method according to claim 1 , wherein an acetate concentration is maintained between 160-500 mmol/L.5: The method according to claim 1 , wherein the aqueous medium further comprises a non-detectable concentration of glucose.6: The method according to claim 1 , wherein the acetate is selected from the group consisting of NaAc and HAc.7: The method according to claim 1 , wherein the at least one alkane comprises at least 6 carbon atoms.8: The method according to claim 1 , wherein the at least one alkane is selected from the group consisting of C-Calkanes.9: The method according to claim 1 , wherein the at least one alkane is selected from the group consisting of C-Calkanes.10Candida, ...

Подробнее

Номер записи: 88

23-01-2020 дата публикации

MICROORGANISM PRODUCING O-ACETYL HOMOSERINE AND THE METHOD OF PRODUCING O-ACETYL HOMOSERINE USING THE SAME

Номер: US20200024626A1

Автор: BAE Jee Yeon, CHOI Jin Geun, Kim Hyun Ah, KIM Sang Kyoum, Kim So Young, Na Kwang Ho, SEO Ju Hee, Shin Yong Uk, Son Sung Kwang, YOO Hye Ryun

Принадлежит: CJ CHEILJEDANG CORPORATION

Disclosed is a microorganism of sp. producing O-acetyl homoserine, and a method of producing O-acetyl homoserine in high yield using the microorganism. 1. A method for producing L-methionine , comprising:{'i': 'Escherichia', '(a) culturing a microorganism of sp. producing O-acetyl homoserine,'}wherein in the microorganism, the endogenous activity of citrate synthase is attenuated or inactivated, and a homoserine O-acetyltransferase is further introduced or enhanced, or an endogenous homoserine O-succinyltransferase is further modified to a polypeptide having 95% identity or above with SEQ ID NO: 16 and further having mutations at the G111E position and L112T or L112H positions to have the activity of homoserine O-acetyltransferase; and(b) contacting O-acetyl homoserine produced in step (a) with O-acetyl homoserine sulfhydrylase, or a microorganism having O-acetyl homoserine sulfhydrylase.2. The method according to claim 1 , wherein the microorganism with the attenuated endogenous activity of citrate synthase has an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.3. The method according to claim 1 , wherein in the microorganism claim 1 , the activity of cystathionine gamma synthase claim 1 , homoserine kinase claim 1 , or both is further attenuated or inactivated compared to their endogenous activities.4. The method according to claim 1 , wherein in the microorganism claim 1 , the activity of at least one protein selected from the group consisting of phosphoenolpyruvate carboxylase claim 1 , aspartate aminotransferase claim 1 , and aspartate semialdehyde dehydrogenase is further introduced or enhanced.5Escherichia coli.. The method according to claim 1 , wherein the microorganism is6LeptospiraChromobacteriumHyphomonas. The method according to claim 1 , wherein O-acetyl homoserine sulfhydrylase is derived from sp. claim 1 , sp. claim 1 , or sp.7. The method according to claim 1 , further comprising adding methylmercaptan as substrate in step (b).8. The method ...

Подробнее

Номер записи: 89

28-01-2021 дата публикации

METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION

Номер: US20210024900A1

Автор: KIRKWOOD Carl, TOMPKINS Stephen M., Tripp Ralph A.

Принадлежит:

Disclosed are compositions and methods for increasing Rotavirus production. 1. A method of increasing Rotavirus production of one or more Rotaviruses comprising infecting a cell with a Rotavirus; wherein the cell comprises reduced expression of at least one gene selected from ZNF205 , NEU2 , NAT9 , SVOPL , COQ9 , BTN2A1 , PYCR1 , EP300 , SEC61G , NDUFA9 , RAD51AP1 , COX20 , MAPK6 , WDR62 , LRGUK , CDK6 , KIAA1683 , CRISP3 , GRPR , DPH7 , GEMIN8 , KIAA1407 , RFXAP , SMARRCA4 , CCDC147 , AACS , CDK9 , C7ORF26 , ZDHHC14 , RNUT1 , GAB1 , EMC3 , FAM96A , FAM36A , LOC55831 , LOC136306 , DEFB126 , MGC955 , EPHX2 , SRGAP1 , PPPSC , MET , SELM , TSPYL2 , TSARG6 , NDUFB2 , PLAU , FLJ36888 , ADORA2B , FLJ22875 , HMMR , NRK , LRIT3 , FLJ44691 , GPR154 , ZGPAT , DRD1 , FLJ27505 , EDG5 , SNRNP40 , HPRP8BP , GPA33 , JDP2 , FLJ20010 , FOXJ1 , SCT , CHD1L , SULT1C1 , STN2 , MRS2L , RAD51AP1 , DPH7 , CLPP , ZNF37 , AP3B2 , DEGS2 , PIR , D2LIC , CNTF , PAM , MYH9 , PRPF4 , SLC4A11 , LRRCC1 , FZD9 , GPR43 , LTF , ARIH1 , PIK3R3 , PTGFRN , HSPA5BP1 , ZDHHC16 , KIAA1764 , C19ORF14 , FLNA , FLJ32786 , DKFZP434K046 , C9ORF112 , and/or PIR51.2. The method of claim 1 , wherein the gene expression is reduced at least 15% relative to a control.3. The method of claim 1 , wherein the reduction occurs through a mutation in a regulator region operably linked to the coding region for ZNF205 claim 1 , NEU2 claim 1 , NAT9 claim 1 , SVOPL claim 1 , COQ9 claim 1 , BTN2A1 claim 1 , PYCR1 claim 1 , EP300 claim 1 , SEC61G claim 1 , NDUFA9 claim 1 , RAD51AP1 claim 1 , COX20 claim 1 , MAPK6 claim 1 , WDR62 claim 1 , LRGUK claim 1 , CDK6 claim 1 , KIAA1683 claim 1 , CRISP3 claim 1 , GRPR claim 1 , DPH7 claim 1 , GEMIN8 claim 1 , KIAA1407 claim 1 , RFXAP claim 1 , SMARRCA4 claim 1 , CCDC147 claim 1 , AACS claim 1 , CDK9 claim 1 , C7ORF26 claim 1 , ZDHHC14 claim 1 , RNUT1 claim 1 , GAB1 claim 1 , EMC3 claim 1 , FAM96A claim 1 , FAM36A claim 1 , LOC55831 claim 1 , LOC136306 claim 1 , DEFB126 claim 1 , MGC955 ...

Подробнее

Номер записи: 90

28-01-2021 дата публикации

GENETICALLY ENGINEERED MICROORGANISMS AND PROCESSES FOR THE PRODUCTION OF CANNABINOIDS FROM A CARBON SOURCE PRECURSOR

Номер: US20210024968A1

Автор: CHAN Brian, DAVIDOVICH Adam, Gupta Neil, Ladha Alim

Принадлежит:

A method is provided for biosynthetic production of cannabinoids in microorganisms from a carbon source precursor. This method describes the genetic modifications needed to engineer microorganisms to produce cannabinoids as well as a method for identifying and quantifying cannabinoids from fermentation broth. A system is also provided for tuning the method to produce different cannabinoids of interest by systematically modulating the enzymes encoded by the genetic modifications introduced in the microorganism. 1. A method for producing at least one cannabinoid from a carbon source precursor , comprising:genetically modifying a microorganism to express enzymes for converting the carbon source precursor into at least one cannabinoid within the genetically modified bacterial strain.2. The method according to claim 1 , wherein the carbon source precursor is glucose and the method further comprises converting the glucose to hexanoate.3. The method according to claim 2 , wherein the at least one cannabinoid comprises cannabigerolic acid.4E. coli.. The method according to claim 3 , wherein the microorganism is a bacterial strain5. The method according to claim 4 , wherein genetically modifying the bacterial strain comprises recombinantly incorporating a mutated FadD gene at the genomic location of a FadE gene of the bacterial strain to express the mutated FadD enzyme and simultaneously knock out the FadE gene of the bacterial strain.6. The method according to claim 5 , wherein the mutated FadD gene comprises a nucleotide sequence of SEQ ID NO: 10.7. The method according to claim 4 , wherein genetically modifying the bacterial strain comprises transforming the bacterial strain to express olivetol synthase claim 4 , olivetolic acid cyclase claim 4 , and CsPT1.8. The method according to claim 7 , wherein the olivetol synthase comprises a first amino acid sequence comprising the amino acid sequence of SEQ ID NO: 2 claim 7 , wherein the olivetolic acid cyclase comprises a ...

Подробнее

Номер записи: 91

29-01-2015 дата публикации

PEGYLATED FIBRINOGEN PRECURSOR MOLECULE

Номер: US20150030580A1

Автор: Almany Liora, Seliktar Dror

Принадлежит:

The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration. 1. A composition comprising a precursor molecule which comprises a fibrinogen protein which is denatured and retains an activity of forming a scaffold and at least two PEG molecules covalently connected to free thiol groups of said denatured fibrinogen protein , each of said at least two PEG molecules comprising a functional group for cross-linking , the composition further comprising pegylated fibronectin.2. The composition of claim 1 , further comprising a plasma derivative protein.3. The composition of claim 2 , wherein said plasma derivative protein is factor XIII.4. The composition of claim 1 , wherein said PEG is selected from the group consisting of PEG-acrylate (PEG-Ac) and PEG-vinylsulfone (PEG-VS).5. The composition of claim 4 , wherein said PEG-Ac is selected from the group consisting of PEG-DA claim 4 , 4-arm star PEG multi-Acrylate and 8-arm star PEG multi-Acrylate.6. The composition of claim 5 , wherein said PEG-DA is a 4-kDa PEG-DA claim 5 , 6-kDa PEG-DA claim 5 , 10-kDa PEG-DA claim 5 , 14-kDa PEG-DA and/or 20-kDa PEG-DA.7. The composition of claim 5 , wherein a molar ratio of PEG-DA:fibrinogen is 2-400:1.8. The composition of claim 1 , wherein said fibrinogen or collagen protein retains an activity of mediating tissue regeneration following in vivo administration.9. A method of generating a scaffold comprising: (a) obtaining a composition of matter comprising plasma-purified fibrinogen; (b) generating a plurality of precursor molecules from said composition of matter and PEG which comprise a fibrinogen protein which is denatured and retains an activity of forming a scaffold and at least two PEG molecules covalently connected to free thiol ...

Подробнее

Номер записи: 92

01-02-2018 дата публикации

METHODS OF DIAGNOSING AND TREATING ALZHEIMER'S DISEASE WITH S-EQUOL

Номер: US20180028491A1

Автор: JACKSON Richard L.

Принадлежит: AUSIO PHARMACEUTICALS, LLC

The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease. 1. A method for the treatment and/or prevention of Alzheimer's disease comprising administering a pharmaceutically effective amount of a formulation comprising S-equol to a subject in need thereof.2. The method of claim 1 , wherein the subject has been diagnosed with Alzheimer's disease.3. The method of claim 1 , wherein the subject is at risk of developing Alzheimer's disease.4. The method of claim 1 , wherein said subject is a human.5. The method of claim 4 , wherein said subject is a human above the age of 50.6. The method of claim 1 , wherein the S-equol is produced chemically.7. The method of claim 1 , wherein the S-equol is not produced biosynthetically or by biotransformation.8. The method of claim 1 , wherein the S-equol is a single anhydrous crystalline polymorph having the following characteristic X-ray powder diffraction pattern wavenumbers (cm): 3433 claim 1 , 3023 claim 1 , 3003 claim 1 , 2908 claim 1 , 2844 claim 1 , 1889 claim 1 , 1614 claim 1 , 1594 claim 1 , 1517 claim 1 , 1508 claim 1 , 1469 claim 1 , 1454 claim 1 , 1438 claim 1 , 1400 claim 1 , 1361 claim 1 , 1323 claim 1 , 1295 claim 1 , 1276 claim 1 , 1261 claim 1 , 1234 claim 1 , 1213 claim 1 , 1176 claim 1 , 1156 claim 1 , 1116 claim 1 , 1064 claim 1 , 1020 claim 1 , 935 claim 1 , 897 claim 1 , 865 claim 1 , 840 claim 1 , 825 claim 1 , 810 claim 1 , 769 claim 1 , 734 claim 1 , 631 claim 1 , 616 claim 1 , 547 claim 1 , 517 claim 1 ...

Подробнее

Номер записи: 93

17-02-2022 дата публикации

Method for Modification of Mung Bean Protein and Preparation of Simulated Egg Pulp based on the Modified Protein

Номер: US20220046964A1

Автор: Jiang Jiang, Liu Yuanfa, Wang Ying, XIONG Youling, Zhang Shucheng

Принадлежит:

The present disclosure discloses a method for modification of mung bean protein and preparation of simulated egg pulp based on the modified protein. A commercial mung bean protein isolate is used as a raw material in the present disclosure, then subjected to pH shift modification, ultrasonic treatment and protein-glutaminase treatment for compound modification to prepare a high-functionality modified mung bean protein isolate; and the modified mung bean protein isolate is used as a raw material, using high-speed emulsification and high-pressure homogenization are conducted to obtain a high-stability mung bean protein-based simulated egg pulp. In the present disclosure, the mung bean protein isolate prepared by compound modification has good solubility, emulsifying property and gelling property. The mung bean protein-based simulated egg pulp is in the form of a stable emulsion and has good fluidity and moderate gelling property, and uniformity and stability can still be maintained for a long time. 1. A method for compound modification of a mung bean protein isolate , comprising: by using the mung bean protein isolate as a raw material , conducting pH shift modification , an ultrasonic treatment and a protein-glutaminase (PG enzyme) treatment for compound modification to prepare a modified mung bean protein isolate.2. The method according to claim 1 , wherein said conducting the pH shift modification claim 1 , the ultrasonic treatment and the protein-glutaminase treatment comprises: first claim 1 , preparing a mung bean protein isolate solution with a mass fraction of 6% to 12% claim 1 , adjusting pH to 10-12 claim 1 , and conducting a treatment at 20° C. to 30° C. for 10-60 minutes; then claim 1 , adjusting the pH to 6-8 claim 1 , and conducting an ultrasonic treatment with a frequency of 10-40 kHz for 10-60 minutes after pH shift is conducted; and next claim 1 , adding a PG enzyme which is 0.1% to 1% of a mass of the mung bean protein isolate for treatment for 10-40 ...

Подробнее

Номер записи: 94

02-02-2017 дата публикации

PLASTIDIC CARBONIC ANHYDRASE GENES FOR OIL AUGMENTATION IN SEEDS WITH INCREASED DGAT EXPRESSION

Номер: US20170029836A1

Автор: DAMUDE HOWARD GLENN, MEYER KNUT, Ripp Kevin G., Stecca Kevin L.

Принадлежит:

Recombinant DNA constructs comprise plastidic carbonic anhydrase coding sequences operably linked to polynucleotides encoding DGAT or transcription factors such as ODP1. These constructs can be used to increase oil content in plants and seeds to levels that are not achieved with DGAT alone. 1. A recombinant DNA construct comprising a first regulatory sequence operably linked to a first heterologous polynucleotide encoding a plastidic carbonic anhydrase polypeptide and a second regulatory sequence operably linked to a second heterologous polynucleotide encoding a diacyldlycerol acyltransferase (DGAT) , polypeptide , wherein expression of the recombinant DNA construct in a transgenic soybean seed results in an increased oil content in a transgenic soybean seed , when compared to a control seed that expresses the second polypeptide but does not express the first polypeptide.2. The recombinant construct of wherein the second heterologous polynucleotide further encodes a polypeptide selected from the group consisting of: an Ovule Development Protein 1 (ODP1) claim 1 , polypeptide claim 1 , a leafy cotyledon1 (Lec1) polypeptide and a transcription factor FUS3 (FUSCA3) polypeptide.3. (canceled)4. The recombinant construct of claim 1 , wherein said recombinant construct further comprises a third polynucleotide downregulating galactinol synthase activity claim 1 , wherein the first heterologous polynucleotide claim 1 , the second heterologous polynucleotide and the third polynucleotide can be in the same construct or in separate constructs.5. The recombinant construct of claim 1 , wherein the first regulatory sequence and the second regulatory sequence each comprise a different seed-specific promoter.6. (canceled)7. The recombinant construct of wherein the percent increase in oil content is at least 5%.8. The recombinant construct of claim 1 , wherein the carbonic anhydrase polypeptide comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:5 claim ...

Подробнее

Номер записи: 95

02-02-2017 дата публикации

ACID-TOLERANT YEAST CELL, METHOD OF PRODUCING ORGANIC ACID USING THE SAME, AND METHOD OF PRODUCING THE YEAST CELL

Номер: US20170029853A1

Автор: Cho Hwayoung, Cho Kwangmyung, Chu Hunsu, Park Jinhwan, Rhee Hongsoon, Yang Dongsik

Принадлежит:

Provided is an acid-tolerant yeast cell, a method of producing an organic acid by using the yeast cell, and a method of producing the yeast cell resistant to acid. 1. An acid-tolerant genetically engineered yeast cell comprisinga genetic modification that increases activity of an enzyme that catalyzes conversion of phosphatidylinositol (PI) and ceramide to inositol phosphorylceramide (IPC) and diacylglycerol (DG);a genetic modification that increases activity of an enzyme, which catalyzes introduction of a double bond to a fatty acyl site of a fatty acyl-CoA;a genetic modification that decreases activity of an enzyme, which catalyzes formation of triacylglycerol (TG) from diacylglycerol (DG) ora combination of the genetic modifications.2. The yeast cell of claim 1 , wherein the enzyme claim 1 , which catalyzes formation of IPC is an IPC synthase; the enzyme that catalyzes introduction of a double bond to a fatty acyl site of a fatty acyl-CoA is an enzyme that belongs to enzyme code (EC) 1.14.19.1; and the enzyme that catalyzes formation of TG from DG is selected from the group consisting of enzymes that belong to EC 2.3.1.22 and 2.3.1.158.3. The yeast cell of claim 2 , wherein the IPC synthase is AUR1; the enzyme claim 2 , which catalyzes introduction of a double bond to a fatty acyl site of a fatty acyl-CoA is OLE1; and the enzyme claim 2 , which catalyzes formation of triacylglycerol (TG) from diacylglycerol (DG) is DGA1 or LRO1.4. The yeast cell of claim 3 , wherein the AUR1 is a polypeptide having at least 95% of sequence identity with amino acid sequence of SEQ ID NO:1 claim 3 , OLE1 is a polypeptide each having at least 95% of sequence identity with amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5 claim 3 , DGA1 is a polypeptide having at least 95% of sequence identity with amino acid sequence of SEQ ID NO:7 claim 3 , and LRO1 is a polypeptide having at least 95% of sequence identity with amino acid sequence of SEQ ID NO: 9.5. The yeast cell of claim 1 , ...

Подробнее

Номер записи: 96

01-02-2018 дата публикации

The use of glycerol with limited feed of carbohydrates for fermentation

Номер: US20180030418A1

Автор: Christian Riedele, Esther DANTAS COSTA, Gregory Von Abendroth, Hartwig Schröder, Joanna Martyna KRAWCZYK, Oskar Zelder, Stefan Haefner, Torsten Renz

Принадлежит: BASF SE

The present invention relates to a process for producing an organic acid by fermentation, comprising the process steps: I) cultivating microorganisms in a culture medium to which are fed, as assimilable carbon sources, glycerol and a further carbonaceous compound, to allow the microorganisms to produce the organic acid, thereby obtaining a fermentation broth comprising the organic acid; II) recovering the organic acid or the salt thereof from the fermentation broth obtained in process step I); wherein, at least for a certain period of time in process step I), the consumption rate of the further carbonaceous compound (C Rc.c.; in g per liter per hour) is lower than the maximum theoretical consumption rate of the further carbonaceous compound (CR c.c. max; in g per liter per hour).

Подробнее

Номер записи: 97

04-02-2021 дата публикации

Methods And Compositions For Consumables

Номер: US20210030014A1

Автор: "BROWN PATRICK OREILLY", CASINO MONTE

Принадлежит:

Provided herein are methods and compositions for the production of cheese replicas. Generally the cheese replicas are produced by inducing the enzymatic curdling of non-dairy milks. 130-. (canceled)31. A method of preparing a non-dairy milk composition comprising:(a) providing an aqueous composition comprising one or more isolated, enriched, or purified plant proteins, one or more oils or fats, and a fermentable carbon source;(b) forming a colloidal suspension, solution, or emulsion from the aqueous composition; and{'i': Penicillium camemberti, Geotrichum candidum, Penicillium roqueforti, Penicillium nalgiovensis, Verticillium lecanii, Kluyveromyces lactis, Saccharomyces cerevisiae, Candida utilis, Debaryomyces hansensil, Rhodosporidum infirmominiatum, Candida jefer, Cornybacteria, Micrococcus', 'Lactobacillus', 'Lactococcus, Staphylococcus, Halomonas, Brevibacterium, Psychrobacter,', 'Streptococcus thermophilus, Pediococcus, '(c) fermenting the colloidal suspension, solution, or emulsion using one or more microbes selected from the group consisting of sps., sps., Leuconostocaceae, sps., and Propionibacteria.'}32. The method of claim 31 , wherein the fermentable carbon source is selected from the group consisting of a disaccharide claim 31 , a fruit juice claim 31 , a monosaccharide claim 31 , agave syrup claim 31 , an oligosaccharide claim 31 , high-fructose corn syrup claim 31 , honey claim 31 , molasses claim 31 , refined sugars claim 31 , sugar-cane extract claim 31 , treacle claim 31 , and mixtures thereof.33. The method of claim 31 , wherein the aqueous composition further comprises an organic acid.34. The method of claim 33 , wherein the organic acid is selected from the group consisting of acetic acid claim 33 , citric acid claim 33 , lactic acid claim 33 , malic acid claim 33 , malonic acid claim 33 , propionic acid claim 33 , and mixtures thereof.35. The method of claim 31 , wherein the one or more isolated plant proteins are selected from the group ...

Подробнее

Номер записи: 98

17-02-2022 дата публикации

METHOD FOR PROMOTING N-ACETYLGLUCOSAMINE SYNTHESIS BY USING GLCN6P RESPONSIVE ELEMENT

Номер: US20220049280A1

Автор: Chen Jian, Chen Taichi, Du Guocheng, Li Jianghua, Liu Long, WU Yaokang

Принадлежит:

The present invention provides a method for promoting N-acetylglucosamine synthesis by using the GlcN6P responsive element. In the present invention, BSGNY-P-glmS-P-GNA1 is used as a starting strain, in which a CRISPRi system regulated by GlcN6P responsive element is integrated into the genome to dynamically weaken the N-acetylglucosamine synthesis competitive pathway; a GlcN6P responsive promoter is used to regulate the expression of GNA1 on the plasmid to dynamically regulate the N-acetylglucosamine synthesis pathway; and the key gene alsSD involved in the acetoin synthesis pathway is knocked out. During fed-batch fermentation with this strain in a 15 L fermenter, the production of N-acetylglucosamine reaches 131.6 g/L and no by-product acetoin is accumulated, which lays a foundation for the production of GlcNAc by industrial fermentation. 1. A method for promoting N-acetylglucosamine synthesis , comprising controlling the expression of glucosamine 6-phosphate N-acetyltransferase GNA1 by using aGlcN6P responsive element to dynamically regulate the N-acetylglucosamine synthesis pathway; and using the GlcN6P responsive element to regulate a compound formed by binding the expressed dCas9 protein to three sgRNA expression fragments acting on zwf , pfkA and glmM genes , to dynamically weaken the glycolysis pathway , the pentose phosphate pathway and the peptidoglycan synthesis pathway , wherein the GlcN6P responsive element comprises the transcription factor GamR and a promoter containing a GamR binding site , where the transcription factor GamR has an amino acid sequence comprising positions 1-235 of an amino acid sequence deposited under NCBI Accession No.: WP_015382651.1 , and the promoter is a Ppromoter or a hybrid promoter constructed by adding a GamR binding site to a constitutive promoter.2. The method according to claim 1 , wherein the promoter Phas a nucleotide sequence as shown in SEQ ID NO: 5.3. The method according to claim 1 , wherein the glucosamine 6- ...

Подробнее

Номер записи: 99

30-01-2020 дата публикации

STRUCTURING FATS AND METHODS OF PRODUCING STRUCTURING FATS

Номер: US20200032302A1

Автор: Bhat Riyaz, Bond Risha, Braksmayer Diza, Franklin Scott, Marangoni Alejandro, Rakitsky Walter, Rudenko George, Somanchi Aravind, ZHAO Xinhua

Принадлежит:

Recombinant DNA techniques are used to produce oleaginous recombinant cells that produce triglyceride oils having desired fatty acid profiles and regiospecific or stereospecific profiles. Genes manipulated include those encoding stearoyl-ACP desaturase, delta 12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, and lysophosphatidic acid acyltransferase. The oil produced can have enhanced oxidative or thermal stability, or can be useful as a frying oil, shortening, roll-in shortening, tempering fat, cocoa butter replacement, as a lubricant, or as a feedstock for various chemical processes. The fatty acid profile can be enriched in midchain profiles or the oil can be enriched in triglycerides of the saturated-unsaturated-saturated type. 198-. (canceled)99. A microbial oil comprising triglycerides , wherein the microbial oil has an altered fatty acid profile relative to a microbial oil produced by a non-recombinant oleaginous microbe , the microbial oil comprising at least 45% of triglycerides being a combination of palmitic-oleic-palmitic triglyceride , stearic-oleic-stearic triglyceride , and palmitic-oleic-stearic triglyceride , and wherein the oleaginous microbe comprises an exogenous gene encoding ketoacyl-ACP synthase (KAS).100. The microbial oil of claim 99 , wherein the ketoacyl-ACP synthase is selected from the group consisting of KASI claim 99 , KASII claim 99 , KASIII or KASIV.101. The microbial oil of claim 100 , wherein the ketoacyl-ACP synthase is KASII.102. The microbial oil of claim 101 , wherein the KASII has at least 95% sequence identity to a protein encoded by nucleotides 4039 to 5328 of SEQ ID NO: 95.103. The microbial oil of claim 99 , wherein the oleaginous microbe further comprises an exogenous gene that encodes a fatty acyl-ACP thioesterase claim 99 , lysophosphatidic acid acyltransferase (LPAAT) claim 99 , or sucrose invertase.104. The microbial oil of claim 99 , wherein the oleaginous microbe further comprises nucleic acids ...

Подробнее

Номер записи: 100